|Publication number||US5696157 A|
|Application number||US 08/749,753|
|Publication date||Dec 9, 1997|
|Filing date||Nov 15, 1996|
|Priority date||Nov 15, 1996|
|Publication number||08749753, 749753, US 5696157 A, US 5696157A, US-A-5696157, US5696157 A, US5696157A|
|Inventors||Hui-Ying Wang, Wai-Yee Leung, Fei Mao|
|Original Assignee||Molecular Probes, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (17), Non-Patent Citations (19), Referenced by (187), Classifications (10), Legal Events (7)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The invention relates to compounds useful for fluorescent labeling and detection. In particular, sulfonated aminocoumarins that are useful as fluorescent tracing agents and enzyme substrates, reactive derivatives of sulfonated aminocoumarins useful as labels, and their conjugates.
Fluorescent dyes are known to be particularly suitable for applications in which a highly sensitive detection reagent is desirable. Dyes that are able to preferentially label a specific ingredient or component in a sample enable the researcher to determine the presence, quantity or location of that specific ingredient or component. In addition, specific systems can be monitored with respect to their spatial and temporal distribution in diverse environments.
Coumarin derivatives have been widely used as fluorescent labels or tracers and to prepare fluorogenic substrates for enzymes, especially where a fluorophore having excitation in the ultraviolet and generally blue to blue-green fluorescent emission was desired. In particular, derivatives of 7-aminocoumarin (for example 3-carboxyalkyl derivatives of 7-amino-4-methylcoumarin, as described by Robinson, U.S. Pat. No. 4,956,480 and 7-amino-4-methylcoumarin) and 7-hydroxycoumarin (often called umbelliferone; for example U.S. Pat. No. 4,279,992 to Boguslaski et al. (1981)) have been widely used blue fluorophores for the preparation of reactive dyes, labels for biomolecules, and reporters for enzyme substrates. However, the conventional coumarin dyes used in biological systems possess certain disadvantages: Some derivatives are not particularly soluble in aqueous systems (i.e. biological systems), they do not possess sufficient photostability for extended use, their fluorescence is quenched upon conjugation, particularly to proteins and they have other disadvantageous properties that restrict their use as fluorescent probes.
Selected sulfonated derivatives of 7-aminocoumarin of the invention and their conjugates possess enhanced brightness and photostability, relative to the corresponding nonsulfonated aminocoumarin, as well as having enhanced aqueous solubilities, while still preserving a bright blue fluorescence emission. Additionally, the dyes of the invention possess advantages over nonsulfonated aminocoumarin dyes in their utility as fluorescent probes for membranes.
7-Aminocoumarins have been widely used as fluorescent labels for biological polymers. For example, Robinson in U.S. Pat. No. 4,956,480 to Robinson describes succinimidyl esters and acid chlorides of 7-amino-4-methylcoumarin-3-alkanoic acids and provides examples of their conjugation to proteins. Kocher et al. (EP 0 608 737 A1) describes reactive 7-aminocoumarins that are used as labels for nucleotides, oligonucleotides and nucleic acids. The aminocoumarins of Kocher et al. are not substituted by sulfonic acid groups. 7-Dimethylaminocoumarin-4-acetic acid, succinimidyl ester has been conjugated to scorpion toxins by Angelides et al. (J. BIOL. CHEM. 258, 11948 (1983)).
Nonsulfonated aminocoumarin derivatives in which the amine is modified by a reactive triazine have been used as brightening agents; for example 7-((4-chloro-6-diethylamino)-s-triazin-2-yl)amino-3-phenylcoumarin.
Various sulfonated coumarins have also been described in the chemical literature; however, none of these has been a 7-aminocoumarin that has been sulfonated at one or more of the 3-, 6- or 8-positions, as required by the present invention.
Abd-El-Hafez et al. (EGYPT. J. PHARM. SCI. 35, 113, (1994)) describes the reaction of 6-nitrocoumarin-3-sulfonyl chloride with a variety of amines to yield the corresponding 6-nitrocoumarin-3-sulfonamide derivatives, which were then tested against bacteria, yeast and fungus for antimicrobial activity. Mandour et al. (EGYPT. J. PHARM. SCI. 36, 71 (1995)) describes coumarin-6-sulfonyl chloride and 6-nitrocoumarin-3-sulfonyl chloride, their sulfonamide derivatives and finally the thiadiazole and selenadiazole derivatives therein, which were tested for antimicrobial and antiaflatoxigenic activity. None of the compounds described above were 7-aminocoumarins, and none of the compounds described were utilized for their fluorescent properties.
Harnisch et al. (DE 3044128 A1) describes sulfonated 7-hydroxycoumarins that are additionally substituted by a heterocyclic moiety that is also typically sulfonated. The dyes are described as useful as fluorescent dyes for cellulose and amide containing materials, for preparing "counterfeit proof" paper and as laser dyes. Sulfonated 7-hydroxycoumarins and 7-alkoxycoumarins have been described, for instance by Merchant et al. (J. INDIAN CHEM. SOC. 34, 35 (1957)). None of the compounds described were 7-aminocoumarins.
The preparation of substituted or unsubstituted 7-aminocoumarin-3-sulfonic acids, 7-aminocoumarin-6-sulfonic acids, 7-aminocoumarin-8-sulfonic acids or 7-aminocoumarin-3,6-disulfonic acids, their chemically reactive derivatives and their conjugates nor their advantages over nonsulfonated 7-aminocoumarins has not been previously described.
FIG. 1: A comparison of the fluorescence spectra in methanol of 7-amino-4-methylcoumarin-3-acetic acid (AMCA) and 7-amino-4-methyl-6-sulfocoumarin-3-acetic acid (Compound 1), recorded at equal dye concentrations. The fluorescence spectra of Compound 1 exhibits enhanced fluorescence relative to the non-sulfonated coumarin, with little shift in emission wavelength.
FIG. 2: A comparison of relative fluorescence of streptavidin conjugates of 7-amino-4-methylcoumarin-3-acetic acid, succinimidyl ester (◯) and the 7-amino-4-methyl-6-sulfocoumarin-3-acetic acid, succinimidyl ester (Compound 2, ). Conjugate fluorescence is determined by measuring the fluorescence quantum yield of the conjugated dye relative to that of the free dye and multiplying by the number of fluorophores per protein (as in Example 22). The conjugates of Compound 2 exhibit enhanced fluorescence with respect to the conjugates of the non-sulfonated dye.
FIG. 3: A comparison of relative fluorescence of goat-anti-mouse antibody conjugates of 7-amino-4-methylcoumarin-3-acetic acid, succinimidyl ester (Δ) and the 7-amino-4-methyl-6-sulfocoumarin-3-acetic acid, succinimidyl ester (Compound 2, ▴). Conjugate fluorescence is determined by measuring the fluorescence quantum yield of the conjugated dye relative to that of the free dye and multiplying by the number of fluorophores per protein (as in Example 22). The conjugates of Compound 2 exhibit enhanced fluorescence with respect to the conjugates of the non-sulfonated dye.
The present invention encompasses 7-aminocoumarin dyes that are substituted one or more times at the 3-, 6- and/or 8-positions by a sulfonic acid or a salt of a sulfonic acid that are useful as fluorescent probes or for preparation of enzyme substrates, caged probes, or adducts with reducing sugars. The dyes of the invention optionally possess a reactive group useful for preparing fluorescent conjugates, which conjugates and methods for their preparation are described herein.
The compounds of the invention are all 7-aminocoumarins substituted one or more times at the 3-, 6- and/or 8-positions by a sulfonic acid or salt of a sulfonic acid, SO3 X, where X is H, or a biologically compatible cation. As used herein, a biologically compatible cation is a cation that is not toxic as used, and does not have a substantially deleterious effect on biomolecules. Examples of biologically compatible cations include, among others, K+, Na+, Cs+, Li+, Ca2+, Mg2+, alkylammonium or alkoxyammonium salts, pyridinium salts, or an inner salt with an amine on the coumarin itself.
The compounds of the invention have the general formula: ##STR1## wherein the substituent R3 is H, SO3 X, halogen, CN, formyl, or NO2. The substituent R4 is H, CN, alkyl having 1-18 carbons, perfluoroalkyl having 1-18 carbons, or sulfomethyl or biologically compatible salt of sulfomethyl (CH2 SO3 X). In one embodiment of the invention, one of R3 and R4 is a reactive group having the formula --L--RX. In another embodiment of the invention, one of R3 and R4 is a conjugated substance having the formula --L--SC. Preferably R3 is H, --L--RX or --L--SC. Preferably R4 is H, methyl, trifluoromethyl, sulfomethyl, --L--RX or --L--SC.
The substituent R5 is H.
The substituent R6 is H, methyl, halogen, or SO3 X.
As used herein, halogen is Cl, Br, I or F. Preferred halogens are F, Cl or Br.
The substituent R7 is either an amine moiety having the formula NR1 R2, or is formally derived from an amine moiety. The amine substituents R1 and R2 are independently H, alkyl having 1-18 carbons, aryl having 6-18 carbons, alkanoyl having 1-18 carbons, or arylalkanoyl having 7-18 carbons. Alternatively R1 in combination with R2 forms a saturated 5- or 6-membered heterocycle that is a piperidine, a morpholine, a pyrrolidine or a piperazine. Preferably R1 and R2 are independently H, methyl or ethyl.
In another embodiment of the invention, R2 is H and R1 is a radical formed by a removal of the hydroxyl group from the carboxylic acid of an amino acid or from the carboxylic acid of the carboxy-terminal amino acid of a linear peptide consisting of 2-6 amino acids. Preferably, R2 is H and R1 is an amide of an amino acid or peptide that is composed of 1-4 amino acids.
Where R1 is derived from an amino acid, the amino acid is a natural or synthetic amino acid, optionally modified on any free amines by carbobenzyloxy (CBZ), p-toluenesulfonyl (tosyl), succinoyl, glutaroyl, acetyl or other protecting groups so as to yield amides and optionally modified on other side-chain functional groups by esterification or alkylation. Where R1 is derived from a peptide, the sequence of the peptide is selected so as to be a suitable enzyme substrate as is known for other 7-aminocoumarin-based substrates. Preferred substrates are those for aminopeptidases and dipeptidyl peptidases. Particularly preferred are substrates for dipeptidyl peptidases I, II and IV, calpain, elastase, trypsin, chymotrypsin, granzyme A, thrombin, cathepsins, urokinase, kallikrein, human adenovirus proteinase, plasminogen activator, interleukin converting enzyme, amyloid A4-generating enzyme, follipsin and leucine aminopeptidase. In one embodiment, substrates wherein R1 is derived from an amino acid or peptide amide are optionally substituted at R3 or R4 by a reactive group (--L--RX) or a conjugated substance (--L--SC).
In another embodiment of the invention, R7 is formally derived from an amine group by replacing the anomeric oxygen atom of an open-ring mono- or polysaccharide derivative with the amine nitrogen, linked by a single or double covalent bond to the anomeric carbon of the saccharide. When the radical is linked by a double bond, the anomeric oxygen atom has been displaced and R7 is a Schiff's base formed between the aminocoumarin and the reducing sugar. When the radical is linked by a single covalent bond, the anomeric oxygen atom has been displaced and R7 can be considered to be derived via reduction of the above Schiff's base. These compound are typically useful as tagging agents, wherein the sulfonic acid(s) on the coumarin provides the ionic charge required for separation by electrophoretic means and the dye provides the means of detection of the analyte.
Alternatively, R2 is H and R1 is a 2-nitrobenzyloxycarbonyl of the formula ##STR2## wherein the aromatic substituents R9 and R10 are H, alkoxy having 1-6 carbons, or R9 and R10 taken in combination are methylenedioxy (--O--CH2 --O--). R11 is H, CH3, a carboxylic acid or a biologically compatible salt of a carboxylic acid.
The substituent R8 is H, halogen, sulfonic acid or biologically compatible salt of sulfonic acid (SO3 X).
For all embodiments of the invention, at least one of R3, R6 and R8 is SO3 X. Preferably one of R3 or R6 or both are SO3 X. More preferably R6 is SO3 X and both R3 and R8 are not SO3 X. In another preferred embodiment, R3 is SO3 X and both R6 and R8 are not SO3 X.
In one embodiment, one of R3 and R4 is --L--Rx ; preferably R3 is --L--RX. In another embodiment of the invention, at least one of R3 and R4 is --L--Sc ; preferably R3 is --L--SC. In an additional embodiment of the invention, one of R3 or R4 is --L--RX or --L--SC and R7 is NR1 R2 where R2 is H and R1 is a radical formed by a removal of the hydroxyl group from the carboxylic acid of an amino acid or from the carboxylic acid of the carboxy-terminal amino acid of a linear peptide consisting of 2-6 amino acids.
Selected embodiments of the present invention are given in Table 1.
TABLE 1__________________________________________________________________________Selected embodiments of the dyes of the present invention__________________________________________________________________________Compound 2 ##STR3##Compound 4 ##STR4##Compound 9 ##STR5##Compound 12a ##STR6##Compound 12b ##STR7##Compound 13a ##STR8##Compound 20 ##STR9##Compound 21 ##STR10##Compound 22 ##STR11##Compound 23 ##STR12##Compound 24 ##STR13##Compound 25 ##STR14##Compound 26 ##STR15##Compound 27 ##STR16##Compound 28 ##STR17##Compound 29 ##STR18##Compound 30 ##STR19##Compound 31 ##STR20##Compound 32 ##STR21##Compound 33 ##STR22##Compound 34 ##STR23##Compound 35 ##STR24##Compound 36 ##STR25##Compound 37 ##STR26##__________________________________________________________________________
Preparation of sulfonated 7-aminocoumarins
Simple sulfonated derivatives of 7-aminocoumarin are typically prepared by sulfonation of a suitably substituted aminocoumarin dye using pure sulfuric acid or fuming sulfuric acid. As is common for sulfonation reactions, the particular reaction conditions can be varied considerably to affect the pattern and extent of sulfonation, as multiple sites may be sulfonated during the sulfonation reaction. Optimization of a given synthesis requires careful evaluation of the reaction conditions and complete analysis of the reaction products. The following general guidelines serve to broadly outline typical patterns of sulfonation:
Sulfonation of simple 4-alkyl-7-aminocoumarins typically yields complex mixtures of product, including low yields of 4-alkyl-7-aminocoumarin-8-sulfonic acids (as in Example 4). Sulfonation of 7-aminocoumarins that are substituted at the 6-position by halogen or lower alkyl also typically yield sulfonation at the 8-position.
Alternatively, when both the 3- and 4-positions of a 7-aminocoumarin are substituted, sulfonation typically occurs exclusively at the 6-position (as in Example 1).
Sulfonation of a 4-alkyl-7-(dialkylamino)coumarin predominantly yields products wherein sulfonation occurs at the 3-position (as in Example 12).
Additional sulfonation of alkyl substituents at the 4-position has also been observed, in particular facilitating the preparation of 7-amino- (or dialkylamino)-4-sulfomethylcoumarin-3-sulfonic acids (as in Examples 8 and 10).
Where the 4-substituent of the aminocoumarin is perfluoroalkyl, sulfonation of 7-amino-4-perfluoroalkylcoumarins yields predominantly substitution of sulfonic acids at the 6-position, or at both the 6- and 3-positions (as in Example 12).
In another synthetic approach, a sulfonated 7-aminocoumarin can be further alkylated under standard condition, such as by dimethyl sulfate. This is the preferred route to 7-dialkylaminocoumarin-6-sulfonic acid derivatives that are not perfluoroalkylated at R4 and that are not additionally sulfonated at the 3-position.
Sulfonic acids are strong acids and form salts with many organic and inorganic bases. Preferred salts are those that yield nonhygroscopic products and include alkali and alkaline earth metals, ammonium and alkylammonium salts. Typically the product is isolated as a zwitterion with the 7-amine substituent of the coumarin, or as the sodium salt. The exact nature of the counterion is typically not important to the application or the preparation of reactive versions of the dyes or their conjugates but may affect the solubility of the dye in the medium.
Sulfonated aminocoumarins that are further substituted by reactive groups, or conjugated substances, are typically prepared by converting an existing dye substituent into a reactive group or --L--RX. Particularly useful candidates for this conversion include coumarin-3-carboxylic acids, coumarin-3-alkanoic acids and coumarin-4-alkanoic acids, 4-halomethylcoumarins (for example Compounds 13b, 23, 29, and 34 in Table 1). These derivatives are easily converted into activated carboxylic acid esters, amines, thiol-reactive probes, hydrazides and other derivatives using conventional chemistry well understood in the art (see, for instance, Examples 2, 5, and 14).
Dye compounds wherein R7 is a nitrogen atom bound to the anomeric carbon atom of a mono- or polysaccharide are typically prepared in situ via a Schiff base followed by reduction, for example with a borohydride.
Conjugates of Reactive Dyes
The dyes of the invention with a reactive group (RX) fluorescently label a wide variety of organic or inorganic substances that contain or are modified to contain functional groups with suitable reactivity, resulting in chemical attachment of the conjugated substance (SC). The reactive group and functional group are typically an electrophile and a nucleophile that generate a covalent linkage upon contact. Alternatively, the reactive group is a photoactivatable group, and becomes chemically reactive only after illumination with light of an appropriate wavelength. Selected examples of functional groups and linkages are shown in Table 2, where the reaction of an electrophilic group and a nucleophilic group yields a covalent linkage.
TABLE 2______________________________________Examples of some routes to useful covalent linkagesElectrophilic Group Nucleophilic Group Resulting Covalent Linkage______________________________________activated esters* amines/anilines carboxamidesacyl azides** amines/anilines carboxamidesacyl halides amines/anilines carboxamidesacyl halides alcohols/phenols estersacyl nitriles alcohols/phenols estersacyl nitriles amines/anilines carboxamidesaldehydes amines/anilines iminesaldehydes or ketones hydrazines hydrazonesaldehydes or ketones hydroxylamines oximesalkyl halides amines/anilines alkyl aminesalkyl halides carboxylic acids estersalkyl halides thiols thioethersalkyl halides alcohols/phenols ethersalkyl sulfonates thiols thioethersalkyl sulfonates carboxylic acids estersalkyl sulfonates alcohols/phenols ethersanhydrides alcohols/phenols estersanhydrides amines/anilines carboxamidesaryl halides thiols thiophenolsaryl halides amines aryl aminesaziridines thiols thioethersboronates glycols boronate esterscarboxylic acids amines/anilines carboxamidescarboxylic acids alcohols esterscarboxylic acids hydrazines hydrazidescarbodiimides carboxylic acids N-acylureas or anhydridesdiazoalkanes carboxylic acids estersepoxides thiols thioethershaloacetamides thiols thioethershalotriazines amines/anilines aminotriazineshalotriazines alcohols/phenols triazinyl ethersimido esters amines/anilines amidinesisocyanates amines/anilines ureasisocyanates alcohols/phenols urethanesisothiocyanates amines/anilines thioureasmaleimides thiols thioethersphosphoramidites alcohols phosphite esterssilyl halides alcohols silyl etherssulfonate esters amines/anilines alkyl aminessulfonate esters thiols thioetherssulfonate esters carboxylic acids esterssulfonate esters alcohols etherssulfonyl halides amines/anilines sulfonamidessulfonyl halides phenols/alcohols sulfonate esters______________________________________ * Activated esters, as understood in the art, generally have the formula --COΩ, where Ω is a good leaving group (e.g. oxysuccinimidyl (--OC4 H4 O2) oxysulfosuccinimidyl (--OC4 H3 O2--SO 3 H),1-oxybenzotriazolyl (--OC6 H4 N3); or an aryloxy group or aryloxy substituted one or more times by electron withdrawing substituents such as nitro, fluoro, chloro, cyano, or trifluoromethyl, or combinations thereof, used to form activated aryl esters; or a carboxylic acid activated by a carbodiimide to form an anhydride or mixed anhydride --OCORa or --OCNRa NHRb, where Ra and Rb, which may be the same or different, are C.sub. -C6 alkyl, C1 -C6 perfluoroalkyl, or C1-C 6 perfluoroalkyl, or C1 -C6 alkoxy; or cyclohexyl, 3dimethylaminopropyl, or Nmorpholinoethyl). ** Acyl azides can also rearrange upon heating to isocyanates
The covalent linkage L binds the reactive group RX or conjugated substance SC to the fluorophore, either directly or with a combination of stable chemical bonds, optionally including single, double, triple or aromatic carbon-carbon bonds, as well as carbon-nitrogen bonds, nitrogen-nitrogen bonds, carbon-oxygen bonds and carbon-sulfur bonds. Generally, L moieties have 1-24 nonhydrogen atoms selected from the group consisting of C, N, O and S; and are composed of any combination of ether, thioether, amine, ester, carboxamide, sulfonamide, hydrazide bonds and aromatic or heteroaromatic bonds. Preferably, L is a single covalent bond or the longest linear segment of the linkage L preferably contains 4-10 nonhydrogen atoms, of which two or fewer are heteroatoms; and comprises one or more carbonyl, carboxamide, polymethylene or phenylene linkages; or an ether or thioether linkage. Carbonyl means --(C═O)--; carboxamide means --(C═O)--NH-- or --NH--(C═O)--; polymethylene means --(CH2)n --, where n=1-12; preferably n=1-5; phenylene means --(C6 H4)--, where the points of attachment are typically para to each other on the phenyl ring. An ether or thioether typically has the formula --(CH2)a --Y--(CH2)b --, where a=0-5, b=1-5, and Y is O or S. In yet another embodiment of the invention, L has the formula --(CH2)a --((C═O)--NH--(CH2)b)z --, where a and b are as defined above, and z is 0 or 1.
The selection of covalent linkage to attach the coumarin to the conjugated substance typically depends on the functional group on the substance to be conjugated. The types of functional groups typically present on the organic or inorganic substances include, but are not limited to, amines, thiols, alcohols, phenols, aldehydes, ketones, phosphates, imidazoles, hydrazines, hydroxylamines, disubstituted amines, halides, epoxides, sulfonate esters, purines, pyrimidines, carboxylic acids, or a combination of these groups. A single type of reactive site may be available on the substance (typical for polysaccharides), or a variety of sites may occur (e.g. amines, thiols, alcohols, phenols), as is typical for proteins. Although some selectivity can be obtained by careful control of the reaction conditions, selectivity of labeling is best obtained by selection of an appropriate reactive dye.
Typically, RX is an acrylamide, a carboxylic acid, an activated ester of a carboxylic acid, a hydroxy, an aldehyde, an alkyl halide, a sulfonate, an amine, an anhydride, an aniline, an aryl halide, an azide, an aziridine, a boronate, a carbodiimide, an epoxide, a glycol, a haloacetamide, a halotriazine, a hydrazine, a hydroxylamine, an isothiocyanate, a ketone, a maleimide, a sulfonyl halide, or a thiol group. Preferably, RX is a carboxylic acid, an activated ester of a carboxylic acid, a hydroxy, an aldehyde, an alkyl halide, an amine, a haloacetamide, a halotriazine, a hydrazine, an isothiocyanate, a maleimide, or a thiol group.
For conjugation to substances having free amine groups, typically dyes are selected wherein L is either a single chemical bond, or L is --(CH2)a --, or L is --(CH2)a --((C═O)(NH(CH2)b)z -- or L is --(CH2)a --Y--(CH2)b -- (where a, b, z and Y are as defined previously) and RX is a carboxylic acid or is an activated ester of a carboxylic acid (which is preferably a succinimidyl). Preferably R6 is SO3 X, R1, R2 and R8 are each H; and, if R3 is --L--RX, then R4 is methyl and, if R4 is --L--RX, then R3 is H. Examples of amine-reactive dyes include Compounds 2, 21, 30, 35, and 36 in Table 1. Amine-reactive dyes are of particular relevance as they are commonly used to label proteins and polypeptides, which possess free amine groups, or for chemical derivatization of amines to be analyzed by chromatographic or electrophoretic means. Amine-reactive dyes are additionally used to label materials that have been substituted with free amine groups, such as amino-dextrans, or amine-containing nucleotides, oligonucleotides, nucleic acids, amine-derivatized polymers or glasses, amine-containing haptens, or amine-containing drugs.
For conjugation to free thiol groups, dyes of the invention typically have RX as a haloalkyl (particularly halomethyl), haloacetamide, halomethylbenzamide, a maleimide group, an epoxide or a sulfonate ester, wherein the sulfonic acid is an alkylsulfonic acid, perfluoroalkylsulfonic acid or an arylsulfonic acid. Preferred thiol-reactive dyes of the invention are those wherein R3 is --L--RX and RX is maleimido or haloacetamido. Additional preferred thiol-reactive dyes of the invention are those wherein R4 is --L--RX and RX is --CH2 Cl or --CH2 Br or RX is maleimido, bromoacetamido or iodoacetamido. Examples include Compounds 23, and 28 in Table 1.
Preferred alcohol- and phenol-reactive dyes are those dyes of the invention wherein RX is a dichloro-s-triazine (e.g. 3,5-dichloro-2,4,6- triazine). In these embodiments, R1 and R2 are typically independently alkyl having 1-6 carbons. Preferred aldehyde- and ketone-reactive groups are hydrazines and carbohydrazides.
Dye-conjugates prepared using photoreactive dyes of the invention (wherein RX is an azide, diazirinyl, azidoaryl (including azidoperfluoroaryl) derivative) require illumination with a suitable wavelength, typically <400 nm. Preferred photoreactive groups are azidotetrafluorophenyl or azidotetrafluorobenzoyl. Alternatively, dye-conjugates containing photoreactive groups (either of the azide, diazirinyl or azidoaryl photocrosslinking type or of those wherein R7 is a caging moiety) are prepared from derivatives that have an additional reactive moiety --L--RX.
Amine- and hydrazine-containing derivatives of the invention are particularly useful for modifying reducing sugars of mono- and polysaccharides. Where R7 is NR1 R2, and R1 and R2 are both H, the aromatic amine at R7 and other aromatic amines that are present in --L--RX, in particular 3-aminocoumarins and 3-aminophenylcoumarins, can be coupled to reducing carbohydrates via Schiff's base formation (as described above) and used for the characterization of those carbohydrates by electrophoretic techniques such as described for aminonaphthalenesulfonic acids e.g. 8-aminonaphthalene-1,3,6-trisulfonic acid (for example Jackson METH. ENZYMOL. 230, 250 (1994)) and 8-aminopyrene-1,3,6-trisulfonic acid (for example O'Shea et al. ELECTROPHORESIS 17, 681 (1996)). Amines are also preferred reactive groups for conjugation to carboxylic acids and activated esters of carboxylic acids.
Useful dye-conjugates of the present invention include conjugates of antigens, steroids, vitamins, metabolites, toxins, environmental pollutants, tyramine, amino acids, peptides, proteins, nucleic acids, nucleic acid polymers, carbohydrates, lipids, ion-complexing moieties, polymers, or cells or cellular components. Typically, the dye-conjugates are conjugates of peptides or proteins; nucleotides, or nucleic acid polymers; iipids; mono- or polysaccharides; therapeutic drugs and drugs of abuse; and pesticides.
Alternatively, the conjugates of the present invention are conjugates of cells, cellular systems, cellular fragments, or subcellular particles. Typically, in this embodiment of the invention the conjugated materials include virus particles, bacterial particles, virus components, biological cells (such as animal cells, plant cells, bacteria, or yeast), or cellular components.
Most preferably, the conjugated substance is an amino acid, peptide, protein, polysaccharide, ion-complexing moiety, nucleotide, oligonucleotide, nucleic acid, hapten, drug, lipid, phospholipid, lipoprotein, lipopolysaccharide, liposome, lipophilic polymer, polymeric microparticle, animal cell, plant cell, bacterium, yeast or virus.
In one embodiment of the invention, the conjugated substance (SC) is an amino acid or a polymer of amino acids such as a peptide or protein. Amino acids mean natural amino acids or their optical isomers, as well as synthetic variations utilized in the art. Common synthetic variations include amino acids that are protected on their amino, carboxylic acid, hydroxy, thiol, imidazole or other functional group. Other modified amino acids are substituted by phosphate, or through glycosylation or acylation with a C1 to C22 carboxylic acid. Peptides generally have molecular weights of less than about 5,000 to 10,000 daltons, and proteins have molecular weights greater than about 5,000 to 10,000 daltons and typically possess secondary, tertiary and/or quaternary structure. Preferred conjugates of peptides contain at least five amino acids, more preferably 5 to 36 amino acids. Preferred peptides to be conjugated to the dyes of the invention include, but are not limited to, neuropeptides, chemotactic peptides, cytokines (such as lymphokines), gastrointestinal peptides, toxins, protease substrates, synthetic peptides, experimental peptides, endothelin and protein kinase substrates. Protein conjugates of the invention include labeled enzymes, antibodies, catalytic antibodies, kinases, lectins, glycoproteins, histories, albumins, lipoproteins, avidin, streptavidin, protein A, protein G, phycobiliproteins, hormones, toxins and growth factors. Typically, the conjugated protein is an antibody, an antibody fragment, avidin, streptavidin, α-bungarotoxin, a lectin, a growth factor, or a phallotoxin.
In another embodiment of the invention, the conjugated substance (SC) is a single nucleic acid base, single nucleoside, single nucleotide or a nucleic acid polymer. A nucleotide comprises an ester of a nucleoside and one or more phosphoric acid or polyphosphoric acid groups, optionally containing an additional linker or spacer for attachment of a fluorophore or other ligand, such as an alkynyl linkage (U.S. Pat. No. 5,047,519 to Hobbs, Jr. et al., (1991), incorporated by reference), an aminoallyl linkage (U.S. Pat. No. 4,711,955 to Ward et al. (1987), incorporated by reference) or other linkage. Nucleotides, as used herein, include natural and synthetic derivatives, including deoxynucleotides, dideoxynucleotides, cyclonucleotides and abasic nucleotide analogs, wherein the base is replaced by a fluorophore or hapten. Preferably, the conjugated nucleotide is a mono-, di- or triphosphate ester of an adenosine, a guanosine, a uridine, a cytidine or a thymidine. More preferably, the conjugated nucleotide is a nucleoside triphosphate or a deoxynucleoside triphosphate or a dideoxynucleoside triphosphate.
Preferred conjugates of nucleic acid polymers are labeled oligonucleotides composed of fewer than 50 nucleotides, more typically composed of fewer than 25 nucleotides. Oligonucleotides are optionally deoxyribonucleic acid polymers (DNA) or ribonucleic acid polymers (RNA), or a hybrid thereof. Nucleic acid polymers are optionally single-stranded or multi-stranded; and may be a natural polymer (biological in origin) or a synthetic polymer (modified or prepared artificially). The nucleic acid polymer optionally incorporates an unusual linker such as morpholine derivatized phosphates (AntiVirals, Inc., Corvallis Oreg.), or peptide nucleic acids such as N-(2-aminoethyl)glycine units (Wittung, et al., NATURE 368, 561 (1994)). In one embodiment of the invention, the dye is attached to the nucleotide, oligonucleotide or nucleic acid polymer via one or more purine or pyrimidine bases through an amide, ester, ether or thioether bond. In another embodiment of the invention, the dye is attached to the phosphate or carbohydrate by a bond that is an ester, thioester, amide, ether or thioether.
In another embodiment of the invention, the conjugated substance (SC) is a carbohydrate, i.e. an organic compound composed of carbon, hydrogen and oxygen and occasionally nitrogen or sulfur, that include sugars, starches and celluloses. The conjugated substance is typically a polysaccharide, such as dextran, FICOL, heparin, glycogen, amylopectin, mannan, inulin, starch, agarose and cellulose, all of which are readily available. Preferred polysaccharide conjugates are dextran or FICOL conjugates, more preferably a dextran conjugate.
In another embodiment of the invention, the conjugated substance (SC), is a lipid. Lipids are long-chain saturated or unsaturated aliphatic hydrocarbons (typically having 6-25 carbons) and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes. The class of lipids includes glycolipids, phospholipids (for example, Compound 37 in Table 1) and sphingolipids. Alternatively, the conjugated substance is a lipid vesicle, such as a liposome, or is a lipoprotein. Alternatively, the dye contains a lipophilic substituent, e.g. where R4 is a linear saturated or unsaturated fatty alkyl group (e.g. Compound 27 in Table 1), typically with 12-18 carbon atoms, wherein one or both of R3 and R6 is SO3 X.
One class of conjugates of the present invention includes conjugates of biologically active molecules. Biologically active molecules include, but are not limited to, drugs, toxins, metabolites, pesticides, pollutants and the like. In one embodiment of the invention, the conjugated substance is a drug or toxin. Where the conjugated substance is a drug, preferred drugs of interest are the alkaloids (including morphine alkaloids), steroids, lactams having from 5 to 6 annular members, aminoalkylbenzenes, benzheterocyclics, purines, marijuana-derived drugs, vitamins, prostaglandins, antibiotics and aminoglycosides, as well as their individual derivatives and metabolites. Metabolites related to diseased states include spermine, galactose, phenylpyruvic acid and porphyrin Type 1. Among pesticides of interest are polyhalogenated biphenyls, phosphate esters, thiophosphates, carbamates, polyhalogenated sulfenamides, their metabolites and derivatives.
The conjugated substance is optionally an ion-complexing moiety. Preferred ion-complexing moieties are crown ether, including diaryldiaza crown ethers, as described in U.S. Pat. No. 5,405,975 to Kuhn et al. (1995); derivatives of 1,2-bis-(2-aminophenoxyethane)-N,N,N',N'-tetraacetic acid (BAPTA), as described in U.S. Pat. No. 5,453,517 to Kuhn et al. (1995), U.S. Pat. No.5,516,911 to London et al., and U.S. Pat. No. 5,049,673 to Tsien et al. (1991) (all incorporated by reference); derivatives of 2-carboxymethoxyaniline-N,N-diacetic acid (APTRA), as described by Ragu et al. AM. J. PHYSIOL. 256, C540 (1989); and pyridine- and phenanthroline-based metal ion chelators, as described in Copending Application 08/384,945, filed Feb. 6, 1995 by Kuhn et al. (incorporated by reference). Preferably the conjugated ion-complexing moiety is a diaryldiaza crown ether chelator or a BAPTA chelator.
Conjugates of non-biological polymers are also useful aspects of the invention, including dye-conjugates of synthetic polymers, polymeric particles (including magnetic and non-magnetic microparticles) polymeric membranes, conducting and non-conducting metals and non-metals, and glass and plastic surfaces and particles. Conjugates are optionally prepared by copolymerization of a coumarin dye that contains an appropriate functionality (for example an acrylic acid- or styryl-substituent) while preparing the polymer, or more commonly by chemical modification of a polymer that contains functional groups with suitable chemical reactivity. In another embodiment of the invention, the conjugated substance is a glass or silica, which may be formed into an optical fiber or other structure. Other types of reactions that are useful for preparing dye-conjugates, especially of polymers, include catalyzed polymerizations or copolymerizations of alkenes, reactions of dienes with dienophiles, and transesterifications or transaminations.
The preparation of dye conjugates using reactive dyes is well documented, e.g. by G. T. Hermanson, BIOCONJUGATE TECHNIQUES (Academic Press 1996); and R. Haugland, MOLECULAR PROBES HANDBOOK OF FLUORESCENT PROBES AND RESEARCH CHEMICALS, Sets 1-7 (1992). Brinkley et al., BIOCONJUGATE CHEM., 3, 2 (1992); Haugland et al., METH. MOL. BIOL. 45, 205 (1995)). Conjugates of the invention typically result from simply mixing the appropriate reactive dyes of the present invention and the substance to be conjugated in a suitable solvent in which both are soluble. Unlike the previously described reactive coumarin derivatives of Robinson supra, the reactive dyes of the invention are directly soluble in water at greater than 1 mM. Water solubility is especially advantageous in labeling of living cells and organic solvent-sensitive proteins. The reaction preferably proceeds spontaneously without added reagents at room temperature or below. For those reactive dyes that are photoactivated, conjugation requires illumination of the reaction mixture to activate the reactive dye.
Preparation of conjugates of biological molecules typically comprises first dissolving the biomolecule to be conjugated in aqueous buffer at ˜1-10 mg/mL at room temperature or below. Preferred buffers include carbonate buffers pH˜8.3 for reaction with succinimidyl esters, phosphate buffers pH˜7.2-8 for reaction with thiol-reactive functional groups and carbonate or borate buffers pH˜9 for reaction with isothiocyanates and dichlorotriazines. The appropriate reactive dye is then dissolved in water or a water-miscible solvent (usually DMSO or DMF) in an amount sufficient to give a suitable degree of conjugation when added to a solution of the biomolecule to be conjugated. The appropriate amount of dye is predetermined by experimentation in which variable amounts of the dye are added to the biomolecule and unconjugated dye is chromatographically removed (Example 22). For all conjugates, an excess of dye is typically used, relative to the expected degree of dye substitution.
Following addition of the reactive dye to the biomolecule, the solution is incubated for a suitable period (typically ˜1 hour at room temperature to several hours on ice), the excess dye is removed by gel filtration, dialysis, HPLC, adsorption on an ion exchange or hydrophobic polymer or other suitable means. The dye-biomolecule conjugate is used in solution or lyophilized. The approximate degree of dye substitution is determined from the absorption of the dye-conjugate (Example 22) or by using the dry weight of the conjugate. The fluorescence in measured as a function of degree of dye substitution (for instance as in Example 23 and FIGS. 2 and 3).
Conjugates of amino acids and peptides through R7 so as to provide enzyme substrates are prepared by organic synthesis using means extensively described for preparation of similar substrates from 7-amino-4-methylcoumarin. Typically, single amino acids suitably protected on their side-chain substituents are conjugated to the 7-aminocoumarinsulfonic acid to form the first amino acid amide then, if appropriate, deprotected and coupled in multiple steps with 1-5 additional amino acids using methods well known in the art of peptide synthesis.
In one aspect of the invention, the conjugate of the invention is associated with an additional substance, that binds either to the fluorophore or the conjugated substance through noncovalent interaction. In a specific embodiment, the additional substance is an antibody to the dye, an enzyme, a hapten, a lectin, a receptor, an oligonucleotide, a nucleic acid, a liposome, or a polymer. The additional substance is optionally used to probe for the location of the dye-conjugate, for example, as a means of enhancing the signal of the dye-conjugate.
In another embodiment of the invention, one of the reactive dyes of the invention is provided in one or more suitable containers with instructions for conjugating the dye to any substance possessing an appropriate functional group, and optionally for recovering or purifying the materials labeled thereby. This combination of reactive dye and instructions therefore comprise a kit for labeling an appropriate substance. Selected appropriate substances include, but are not limited to, polymers of biological molecules (e.g. proteins, oligonucleotides or carbohydrates), polymeric resins and plastics (e.g. polystyrene), metals, glasses, and other organic or inorganic substances. The dyes of the present invention are well-suited for the preparation of such a kit.
Applications and Methods of Use
The dye compounds of the invention are generally utilized by combining an aminocoumarin sulfonic acid derivative described above with the sample of interest under conditions selected to yield a detectable optical response. The term "dye compound" is used herein to refer to all aspects of the claimed sulfonated aminocoumarins, including reactive sulfonated aminocoumarins, conjugates of sulfonated aminocoumarins, lipophilic versions of sulfonated aminocoumarins, substituted sulfonated aminocoumarins for use as enzyme substrates, and additional derivatives. The dye compound typically forms a covalent or non-covalent association or complex with an element of the sample, or is simply present within the bounds of the sample or portion of the sample. Optionally, the sample is washed to remove residual, excess or unbound dye compound. The sample is then illuminated at a wavelength selected to elicit the optical response. Typically, staining the sample is used to determine a specified characteristic of the sample by further comparing the optical response with a standard or expected response.
For biological applications, the dye compounds of the invention are typically used in an aqueous or aqueous-miscible solution prepared according to methods generally known in the art. The exact concentration of dye compound is dependent upon the experimental conditions and the desired results, but typically ranges from about one nanomolar to one millimolar or more. The optimal concentration is determined by systematic variation until satisfactory staining with minimal background fluorescence is accomplished.
The dye compound is combined with the sample in any way that facilitates contact between the dye compound and the sample components of interest. Typically, the dye compound or a solution containing the dye compound is simply added to the sample. Unlike other coumarin derivatives, sulfonated aminocoumarin derivatives tend to be impermeant to membranes of biological cells, and once inside viable cells are typically well retained. Treatments that permeabilize the plasma membrane, such as electroporation, shock treatments or high extracellular ATP can be used to introduce dye compounds into cells. Alternatively, the dye compounds are physically inserted into cells, e.g. by pressure microinjection, scrape loading, patch clamp methods, or phagocytosis. Sulfonated aminocoumarins that incorporate an amine or a hydrazine residue (for example Compound 24 in Table 1) can be microinjected into cells, where they can be fixed in place by aldehyde fixatives such as formaldehyde or glutaraldehyde. Nonsulfonated coumarins are not suitable for such applications because they are not well retained in living cells.
Solubilization of the fluorophore in water by the sulfonic acid and their impermeance to membranes gives the dye compounds of the invention particular utility as polar tracers, according to methods generally known in the art for other dye compounds, see e.g. U.S. Pat. No. 4,473,693 to Stewart (1984) (using lucifer yellow) and U.S. Pat. No. 5,514,710 to Haugland et al. (1996) (using caged hydroxypyrenesulfonic acids) (both patents incorporated by reference). Photolabile or "caged" conjugates permit temporal or spatial control of the fluorogenic compounds. Sulfonated aminocoumarins substituted at R1 by a caging moiety, in particular a 2-nitrobenzyloxycarbonyl substituent (Compound 33 in Table 1 or as in Example 15) exhibit strongly quenched fluorescence properties. The fluorescence of the aminocoumarin is restored by photolysis of the caged probe with ultraviolet light. In this reaction the initially formed N-carboxy derivative spontaneously decomposes to a fluorescent derivative wherein Rl is H. Relative to conventional caged coumarins, the dye compounds of the invention have enhanced photostability and are better able to withstand the intense illumination typically required to photolyze the caging group.
Dye compounds that possess a lipophilic substituent at R4 or that are conjugated to lipophilic molecules such as phospholipids will non-covalently incorporate into lipid assemblies, e.g. for use as probes for membrane structure; or for incorporation in liposomes, lipoproteins, films, plastics, lipophilic microspheres or similar materials; or for tracing. Sulfonated aminocoumarin dyes wherein R4 is a fatty alkyl group are useful as fluorescent probes of membrane structure, wherein the sulfonic acid moiety permits trapping of the probe at or near the membrane's surface.
Chemically reactive dye compounds will covalently attach to a corresponding functional group on a wide variety of materials, forming dye conjugates as described above. Using dye compounds to label reactive sites on the surface of cells, in cell membranes or in intracellular compartments such as organelles, or in the cell's cytoplasm, permits the determination of their presence or quantity, or their spatial and temporal distribution in the sample. Unlike other reactive coumarin derivatives, chemically reactive sulfonated aminocoumarin derivatives tend to be impermeant to membranes of biological cells, giving them utility as fluorescent probes for assessing the topography of protein distribution in living cells. Photoreactive sulfonated aminocoumarins can be used similarly to photolabel components of the outer membrane of biological cells or as photo-fixable polar tracers for cells. Outside of the cellular milieu, the negative charge of the dye compounds at neutral pH also facilitates the electrophoretic separation of dye-conjugates of carbohydrates, drugs and other low molecular weight compounds for analysis by capillary zone electrophoresis (CZE), HPLC or other separation techniques. Precipitation of the conjugate is minimized, even after labeling with multiple fluorophores, since the sulfonated aminocoumarin derivatives are fully ionized at neutral pH.
Alternatively, the dye compound is a conjugate of a specific binding pair member, and is used as a fluorescent probe for the complementary member of that specific binding pair, each specific binding pair member having an area on the surface or in a cavity which specifically binds to and is complementary with a particular spatial and polar organization of the other. Representative specific binding pairs are shown in Table 3. The dye compounds are useful as probes for a complementary binding pair member present in an animal cell, plant cell, bacteria, yeast or virus. Alternatively, the complementary member is immobilized on a solid or semi-solid surface, such as a polymer, polymeric membrane or polymeric particle (such as a polymeric bead). The dye compound may also include a moiety at R7 that is later removed by the action of an enzyme or light, such as a peptide or a caging group.
TABLE 3______________________________________Representative Specific Binding Pairsantigen antibody______________________________________biotin avidin (or streptavidin or anti-biotin)IgG* protein A or protein Gdrug drug receptortoxin toxin receptorcarbohydrate lectin or carbohydrate receptorpeptide peptide receptorprotein protein receptorenzyme substrate enzymeDNA (RNA) aDNA (aRNA)†hormone hormone receptorion chelator______________________________________ *IgG is an immunoglobulin †aDNA and aRNA are the antisense (complementary) strands used for hybridization
The dye conjugates are used according to methods extensively known in the art; e.g. use of antibody conjugates in microscopy and immunofluorescent assays; and nucleotide or oligonucleotide conjugates for nucleic acid hybridization assays and nucleic acid sequencing (e.g., U.S. Pat. Nos. 5,332,666 to Prober, et al. (1994); 5,171,534 to Smith, et al. (1992); 4,997,928 to Hobbs (1991); and WO Appl. 94/05688 to Menchen, et al.; all incorporated by reference). In one embodiment, dye conjugates of the invention are simultaneously labeled with one or more additional dyes, that may be the same or different. In one embodiment, a conjugate is labeled with two or more different dyes that are selected so as to undergo energy-transfer, and analysis of the spectral properties of the conjugate indicates a mechanism or component of the sample, such as in a double labeled peptide, a double-labeled oligonucleotide or a double-labeled protein. Alternatively, the dye-conjugate is simultaneously labeled with a hapten such as biotin or digoxigenin or other detectable label. Where the labeled specific binding pair member is a chelator of calcium, sodium, magnesium, potassium, or other biologically important metal ion, the dye-conjugate functions as an indicator of the ion, which indicators are optionally further conjugated to a biological or plastic polymer according to methods known in the art. One or more sulfonated aminocoumarin dyes conjugated to a biologically compatible polymer, including amino acid polymers (typically proteins, including fluorescent proteins), carbohydrate polymers (typically dextrans), and polymeric microspheres (typically polystyrene) are readily prepared for use as tracers according to methods known in the art, with the solubility advantages described previously. Where the sulfonated aminocoumarin is conjugated to a tyramine as Sc, the resulting dye-conjugate is useful as a substrate for peroxidase enzymes (as described in U.S. Pat. No. 5,196,306 to Bobrow et al. (1993)).
The use of sulfonated aminocoumarins also results in improved fluorogenic enzyme substrates with the appropriate enzyme-cleavable substituent at R7. The increased solubility of the substrate dye compounds is particularly advantageous if the clearable substituent has a low solubility. The enzyme probes of the invention yield products having enhanced fluorescence yield following the enzymatic reaction, relative to their non-sulfonated analogs. Amides of the sulfonated 7-aminocoumarins of the invention also have strongly quenched fluorescence and absorption that is shifted toward the ultraviolet, similar to non-sulfonated derivatives, but their greater water solubility permits preparation of more concentrated aqueous solutions of the substrate, which is beneficial for obtaining pseudo first-order hydrolysis kinetics. Concentrations of dye-conjugates that have utility as enzyme substrates are preferably above the Michaelis-Menton constant (Km) of the enzyme that is being measured, which concentrations are typically in the micromolar to millimolar range.
The sample is optionally combined with one or more other solutions in the course of staining, including wash solutions, permeabilization and/or fixation solutions, and solutions containing additional detection reagents. Where the additional detection reagent has, or yields a product with, spectral properties that differ from those of the subject dye compounds, multi-color applications are possible. Dye compounds of the invention typically have bright blue to blue-green fluorescence (see Table 4) that contrasts well with reagents that give green, yellow, orange or red fluorescence.
TABLE 4______________________________________Spectral properties of selected embodiments of the invention Absorbance max. ε × 10-3 Emission max.Compound (nm) (cm-1 M-1) (nm)______________________________________1 350 19 4344 353 19 4218 413 26 5119 422 27 51512a 371 18 48312b 360 18 473______________________________________
At any time after or during staining, the sample is illuminated with a wavelength of light selected to give a detectable optical response, and observed with a means for detecting the optical response. Upon UV illumination the dye compounds display intense absorption as well as visible fluorescence emission. Equipment that is useful for illuminating the dye compounds of the invention includes, but is not limited to, hand-held ultraviolet lamps, mercury arc lamps, xenon lamps, lasers and laser diodes. These illumination sources are optionally integrated into laser scanners, fluorescence microplate readers, standard or minifluorometers, or chromatographic detectors.
A detectable optical response means a change in, or occurrence of, an optical signal that is detectable either by observation or instrumentally. Typically the detectable response is a change in fluorescence, such as a change in the intensity, excitation or emission wavelength distribution of fluorescence, fluorescence lifetime, fluorescence polarization, or a combination thereof. The degree and/or location of staining, compared with a standard or expected response, indicates whether and to what degree the sample possesses a given characteristic.
The optical response is optionally detected by visual inspection, or by use of any of the following devices: CCD cameras, video cameras, photographic film, laser-scanning devices, fluorometers, photodiodes, quantum counters, epifluorescence microscopes, scanning microscopes, flow cytometers, fluorescence microplate readers, or by means for amplifying the signal such as photomultiplier tubes. Where the sample is examined using a flow cytometer, examination of the sample optionally includes sorting portions of the sample according to their fluorescence response.
The examples below are given so as to illustrate the practice of this invention. They are not intended to limit or define the entire scope of this invention.
Powdered ethyl 7-ethoxycarbonylamino-4-methylcoumarin-3-acetate (U.S. Pat. No. 3,008,969 to Pretka (1961)) (8 g) is added in small portions with stirring to 30% fuming sulfuric acid (10 mL) that is cooled in an ice/water bath. After the addition is complete, the mixture is stirred for 1 hr at 0° C., warmed to room temperature for 2 hours, and then stirred for 3 days at 70° C. The solution is cooled to room temperature and poured into crushed ice (80 g). After standing overnight at room temperature, the resulting precipitate is collected by suction filtration. The precipitate is resuspended in water (20 mL) and the pH of the suspension is adjusted to about 5 by addition of 2M NaOH. The resulting mixture is poured into 1 L of methanol and the suspension is filtered. The filtrate is evaporated to dryness to give crude product, which is further purified on a SEPHADEX LH-20 resin column eluting with water to give 1.75 g (23%) of pure Compound 1. 1 H NMR (d6 -DMSO) δ7.84 (s, 1H); 6.49 (s, 1H); 5.18 (br s, 2H); 3.4 (s (overlapping with H2 O peak), 2H); 2.34 (s, 3H).
To a solution of 1 (1.02 g, 3.26 mmol) in DMF (20 mL) is added 2-succinimido-1,1,3,3-tetramethyluronium tetrafluoroborate (1 g, 3.58 mmol) and N,N-diisopropylethylamine (0.89 g, 6.89 mmol). The solution is stirred at room temperature for 30 min and then concentrated to dryness by vacuum distillation. The crude solid product is purified by flash column chromatography on silica gel eluting with 5% H2 O/CH3 CN to give 1.15 g (65%) of 2 as a pale orange solid. 1 H NMR (d6 -DMSO) δ7.84 (s, 1H); 6.52 (s, 1H); 3.97 (s, 2H); 3.62-3.58 (m, 2H); 3.12-3.06 (m, 2H); 2.78 (s, 4H); 2.32 (s, 3H); 1.25-1.23 (m, 15H).
To 1 (1.2 g, 3.83 mmol) in 30 mL dry pyridine is added 2-succinimido-1,1,3,3-tetramethyluronium tetrafluoroborate in small portions over 5 min. After the solution is stirred for 5 hrs, the solvent is removed by vacuum distillation at room temperature. The gummy solid is triturated with ether 6 times (6×50 mL) and then dried overnight under high vacuum at room temperature. The crude material is subjected to silica gel column chromatography eluting with H2 O/CH3 CN (0-6% H2 O/CH3 CN). Fractions containing the product are pooled and concentrated to about 15 mL by rotary evaporation at 40° C. After the mixture is cooled to room temperature, the resulting pale yellow precipitate is collected by suction filtration, followed by drying under high vacuum at room temperature for 24 hrs to give 0.5 g of 3. 1 H NMR (d6 -DMSO with D2 O exchange) δ7.83 (s, 1H); 6.52 (s, 1H); 3.97 (s, 2H); 2.78 (s, 4H); 2.32 (s, 3H).
To 30% fuming sulfuric acid (3 mL) stirred at 0° C. is added 7-amino-4-methylcoumarin (0.8 g, 4.57 mmol) in one portion. The mixture is stirred at 0° C. for 30 min, then warmed to 60°-70° C. and stirred overnight. After the solution is cooled to room temperature, dioxane (6 mL) is added, followed by the addition of 40 mL of diethyl ether. The resulting precipitate is collected by suction filtration and then suspended in H2 O (50 mL). The pH of the suspension is adjusted to about 5 by adding NaHCO3. The solvent is removed by rotary evaporation to give a crude solid, which is purified using column chromatography on silica gel, eluting with H2 O/CH3 CN to give 0.25 g (20%) of Compound 4. 1 H NMR (d6 -DMSO with D2 O exchange) δ7.35 (d, 1H); 6.62 (d, 1H); 5.91 (s, 1H); 2.33 (s, 3H).
A mixture of Compound 3 (100 mg, 0.24 mmol), N,N-diisopropylethylamine (123 mg, 0.96 mmol) and N-(2-aminoethyl)maleimide trifluoroacetic acid salt (70.8 mg, 0.25 mmol) in DMF (1 mL) is stirred at room temperature overnight. Diethyl ether is added to the reaction mixture, resulting in formation of a precipitate. The resulting solid is filtered and washed with diethyl ether. The crude product is purified by column chromatography on silica gel eluting with 5% H2 O in acetonitrile to give Compound 5 (70 mg, 67%). 1 H-NMR (d6 -DMSO): δ=7.78 (1H, s); 7.0 (2H, s); 6.47 (1H, s); 6.35 (2H, s); 3.46 (2H, m); 3.20 (2H, m), 2.20 (3H, s).
A solution of Compound 3 (70 mg, 0.17 mmol) in DMF (0.3 mL) is added to a solution of 6-aminocaproic acid (41 mg, 0.31 mmol) and K2 CO3 (40 mg, 0.28 mmol) in water (0.3 mL). After the reaction mixture is stirred at room temperature for 1 hr, the solvent is removed under reduced pressure. Methanol is added to the residue, which is then filtered to remove insoluble salts. The resulting filtrate is concentrated to 1 mL and then purified on silica gel column eluting with CHCl3 followed by 5% H2 O in acetonitrile to give Compound 6 (60 mg, 87%). 1 H-NMR (d6 -DMSO): δ=7.80 (1H, s); 6.45 (1H, s); 6.31 (2H, s); 3.40 (2H, s); 3.0 (2H, m), 2.21 (3H, s); 2.10 (2H, m); 1.48 (2H, m); 1.39 (2H, m); 1.24 (2H, m).
To a solution of Compound 6 (66 mg, 0.14 mmol) in dry DMF (1 mL) is added 1,3-diisopropylcarbodiimide (32 mg, 0.27 mmol) and N-hydroxysuccinimide (30 mg, 0.27 mmol). The reaction mixture is stirred at room temperature overnight, and then precipitated by the addition of diethyl ether. The resulting solid is filtered and washed with diethyl ether. The crude product is purified by column chromatography on silica gel eluting with 5% H2 O in acetonitrile to give 7 (30 mg). 1 H-NMR (d6 -DMSO): δ=7.80 (1H, s); 6.5 (1H, s); 6.35 (2H, s); 3.40 (2H, s); 3.02 (2H, m), 2.80 (4H, s); 2.65 (2H, m); 2.25 (3H, s); 1.62 (2H, m); 1.42-1.35 (4H, m).
7-Dimethylaminocoumarin-4-acetic acid (2.3 g, 8.8 mmol; Molecular Probes, Inc., Eugene Oreg.) is added in small portions to 30% fuming sulfuric acid (5 mL) at 0° C., and stirred at 70° C. overnight. The reaction mixture is cooled to below -20° C. Water (5 mL) is slowly added and the reaction mixture is then poured into CH3 CN. The resulting oily precipitate is dissolved in methanol, and slowly poured into CH3 CN. The resulting crude solid is filtered and washed with CH3 CN. The product is crystallized from methanol to give pure Compound 8 (2.0, 78%). 1 H-NMR (d6 -DMSO): δ=7.90 (1H, dd); 6.68 (1H, dd); 6.41 (1H, d); 5.02 (2H, s); 3.0 (6H, s).
7-Diethylamino-4-methylcoumarin (4.66 g, 10 mmol) is added in small portions to 30% fuming sulfuric acid (5 mL) at 0° C., and the resulting solution is stirred at 70°-90° C. overnight. After cooling to room temperature, the reaction mixture is poured into crushed ice (10 g), and allowed to stand overnight at room temperature. The resulting precipitate is collected by suction filtration. The crude product is dissolved in 2M NaOH and then purified by chromatography on a SEPHADEX LH-20 resin column to give pure Compound 9 (2 g). 1 H-NMR (d6 -DMSO): δ=7.90 (1H, dd); 6.65 (1H, dd); 6.36 (1H, d); 5.18 (2H, s); 3.41 (4H, q); 1.10 (6H, t).
7-Aminocoumarin-4-acetic acid (1.5 g, 6.8 mmol; Besson HETEROCYCLES, 34, 273 (1992)) is dissolved in 30% fuming sulfuric acid (3 mL) at 0° C., and then stirred at 70° C. overnight. After cooling to room temperature, the reaction mixture is poured into a minimum amount of crushed ice (5 g). The resulting solution is purified by chromatography on a SEPHADEX LH-20 resin column eluting with water. The pure fractions are pooled and lyophilized to give pure Compound 10 (0.8 g, 39%). 1 H-NMR (d6 -DMSO): δ=7.75 (1H, dd); 6.56 (1H, dd); 6.32 (1H, d); 5.01 (2H, s).
To a solution of t-Boc-Ala-Ala (1.16 g, 5 mmol) in DMF/pyridine (2 mL/2 mL) stirred at 4° C. is added EDAC (1.0 g, 5 mmol), and the reaction mixture is stirred at 4° C. for 30 minutes. To this reaction mixture is added Compound 10 (0.3 g, 1 mmol) in DMF (1 mL) and the resulting mixture is stirred at 4° C. for 2 hours, then at room temperature for 2 days. The solvent is then removed under reduced pressure, and to the resulting residue is added diethyl ether to precipitate the desired product. The crude compound is purified by chromatography on a SEPHADEX LH-20 resin column eluting with water to give Compound 11.
7-Amino-4-trifluoromethylcoumarin (1.5 g, 6.8 mmol) is dissolved in 30% fuming sulfuric acid (3 mL) at 0° C., and then stirred at 70° C. overnight. After cooling to room temperature, the reaction mixture is poured into a minimum amount of crushed ice (5 g). A precipitate forms after standing at room temperature overnight. The solid product is collected by filtration, then dissolved in 1 mL of 2M NaOH and purified by chromatography on a SEPHADEX LH-20 resin column eluting with water to give Compound 12a (0.6 g) and Compound 12b (0.1 g). 12a 1 H-NMR (d6 -DMSO): δ=8.10 (1H, s); 6.72 (1H, s); 6.50 (1H, s). 19 F-NMR (d6 -DMSO): δ=-62.3 ppm. 12b 1 H-NMR (d6 -DMSO): δ=7.88 (1H, s); 6.52 (1H, s). 19 F-NMR (d6 -DMSO): δ=-58.7 ppm
To 30% fuming sulfuric acid (1 mL) at 0° C. is added 7-aminocoumarin-4-acetic acid (100 mg, 0.46 mmol) in one portion. The solution is warmed to room temperature and stirred overnight. The mixture is poured into crushed ice (20 g) and the pH is adjusted to 5-6 by adding powdered NaHCO3. MeOH (150 mL) is added to the above solution, followed by suction filtration. The filtrate is rotary evaporated to dryness to give a crude mixture of Compound 13a (Rf =0.47; 15% H2 O/CH3 CN) and Compound 13b (Rf =0.28; 15% H2 O/CH3 CN), which is purified by chromatography on a SEPHADEX LH-20 resin column eluting with H2 O to give a pure mixture. Compounds 13a and 13b are separated by chromatography on a silica gel column eluting with H2 O/CH3 CN. 1 H NMR (d6 -DMSO with D2 O exchange) for 13a δ7.65 (d, J=9 Hz, 1H); 6.67 (d, J=9 Hz, 1H); 6.66 (s, 1H); 3.92 (s, 2H). 1 H NMR (d6 -DMSO with D2 O exchange) for 13b δ7.54 (d, J=9 Hz); 6.66 (d, J=9 Hz); 6.55 (s, 1H); 6.06 (s, 1H); 5.06 (s, 1H).
Compound 14 is prepared from Compound 13a according to the procedure described in Example 3.
To a solution of Compound 10 (31 mg, 0.1 mmol) in a 1:1 mixture of anhydrous DMF and pyridine (3 mL) stirred at 0° C. is added 4,5-dimethoxy-2-nitrobenzylchloroformate (62 mg, 0.22 mmol) in 1 mL anhydrous THF. The reaction mixture is stirred at 0° C. for 2 hours and then at room temperature overnight. The solvent is removed under high vacuum to give a crude product, which is purified on a silica gel column eluting with 10% H2 O/CH3 CN.
To a solution of Compound 4 (0.5 g) in 15 mL acetic acid at 0° C. is added 1.2 equivalents of 70% HNO3. The reaction mixture is warmed to room temperature, then stirred overnight. The solvent is removed under vacuum, and the residue is purified by chromatography on silica gel eluting with 10% H2 O/CH3 CN, to give Compound 16.
Methanol solutions of Compound 1 and 7-amino-4-methylcoumarin-3-acetic acid (AMCA), respectively, have proven stable at room temperature when carefully shielded from exposure to light. However, when methanol solutions of each dye are exposed to ambient light for 72 hours (room temperature), the AMCA solution becomes yellow in color, while the solution of Compound 1 remains colorless. Thin layer chromatographic analysis (CHCl3 :MeOH:HOAc=8:1.8:0.2) of each solution indicates that the AMCA solution contains three new weakly fluorescent products, each having a higher Rf value than AMCA, while the solution of Compound 1 contains essentially only Compound 1.
To a solution of 2 mg of 5-(3-aminoallyl)-2'-deoxyuridine-5'-triphosphate, ammonium salt (Sigma Chemical) in 300 μL of water is added a solution of 4 mg of Compound 2 (Example 2) in 150 μL of DMF, followed by the addition of 5 μL of triethylamine. After the mixture is stirred at room temperature for 3 hours, it is purified by chromatography over lipophilic SEPHADEX resin using water for elution. The desired fractions are combined and lyophilized to give the fluorescent nucleotide conjugate as an off-white solid.
A sample of 500 μg of a 5'-amine-modified, 24-base M13 primer sequence is dissolved in 220 μL of 0.1M borated sodium bicarbonate pH 8.5 aqueous buffer in a microcentrifuge tube. To this oligonucleotide solution is added a solution of 1 mg of Compound 2 (Example 2) in 35 μL of DMF. The reaction mixture is shaken by hand for a few minutes and allowed to stand at room temperature for 16 hours. To the mixture is added 15 μL of 5M NaCl and 3 volumes of cold 100% ethanol. The resulting mixture is incubated at -20° C. for 30-60 minutes, and then microcentrifuged for 15-30 minutes at 4° C. (5,000-10,000 g). After microcentrifugation, the ethanol supernate is decanted, and the pellet is resuspended in 100 μL H2 O. The labeled oligonucleotide is then purified by HPLC on a 220 mm×10 mm 300 ÅC8 reverse phase column (Rainin Instrument Co., Woburn, Mass.) using the following gradient: Solvent A--0.1M TEAA (pH˜7), Solvent B--acetonitrile. Ramp Solvent B from 15% to 60% over 30 minutes. Detection is accomplished using a Waters 490 dual wavelength UV-Vis detector monitoring 254 nm and 340 nm. The desired peak is collected and evaporated to yield the fluorescent oligonucleotide.
To a solution of 3 mg of aminophalloidin p-toluenesulfonate and 4 mg of Compound 2 in 300 μL of DMF is added 5 μL of triethylamine and the mixture is stirred at room temperature for 1 hour. To the reaction mixture is added 7 mL of ether and the resulting precipitate is collected by centrifugation. The crude product is purified by chromatography over lipophilic SEPHADEX resin using water for elution. The desired fractions are combined and lyophilized to give the fluorescent phalloidin conjugate as a off-white solid.
Biocytin (Molecular Probes, Inc., Eugene, Oreg.) (74.4 mg, 0.2 mmol) and 8 mg NaOH are dissolved in 1 mL water. To the resulting clear solution is added 125 mg (approx. 0.2 mmol) Compound 2 dissolved in 1 mL dimethylformamide. After stirring 2 hours at room temperature, the solution is diluted with 50 mL water and acidified with 1 mL of 1M HCl. The resulting product is collected by centrifugation, washed well with water and dried. The biocytin-dye conjugate is purified by chromatography on silica gel using mixtures of chloroform and methanol for elution. The pure conjugate is characterized by the formation of a fluorescent complex when the conjugate is treated with excess avidin. The resulting complex comigrates with unlabeled avidin on a SEPHADEX G 100 resin filtration column.
Protein conjugates of Compound 2 and 7-amino-4-methylcoumarin-3-acetic acid, succinimidyl ester (AMCA, SE), are prepared. The degree of substitution achieved on the selected proteins (goat anti-mouse IgG (GAM), streptavidin (STR) and wheat germ agglutinin (WGA) is then determined.
A fresh solution of the desired protein is prepared that is 10 mg protein/mL in 0.1M sodium bicarbonate. The desired labeling reagent (Compound 2 or 7-amino-4-methylcoumarin-3-acetic acid, succinimidyl ester) is dissolved in DMF to give a concentration of 10 mg dye/mL. An amount of the labeling reagent in DMF sufficient to give the desired dye:protein ratio is slowly added to the protein solution with stirring. A molar ratio of 10 equivalents dye to equivalent of protein is typical, though the optimal amount varies with particular labeling reagent and protein being labeled. The reaction mixture is then incubated at room temperature for one hour. The dye-protein conjugate is separated from free unreacted reagent by gel filtration on a CELLUFINE GH-25 column equilibrated in PBS. The initial, protein-containing blue fluorescent band is collected from the column, and the degree of substitution is determined by measuring the absorbance of the conjugate at 346 nm, and calculating the degree of substitution using an extinction coefficient of 14,000 cm-1 M-1 for AMCA and 20,000 cm-1 M-1 for Compound 2).
Using the above method, conjugates of streptavidin (STR), wheat germ agglutinin (WGA) and goat anti-mouse (GAM) are prepared using both Compound 2 and 7-amino-4-methylcoumarin-3-acetic acid, succinimidyl ester. The resulting degree of substitution of the proteins is then compared as a function of dye:protein ratio:
As shown above, the conjugates of the present invention exhibit a similar degree of dye incorporation into streptavidin and GAM, and even higher incorporation in WGA, at similar molar ratios of reactive dye to protein.
The total fluorescence of selected dye-conjugates of the present invention is plotted against the degree of substitution of the selected conjugates. Measured total fluorescence is a product of both the degree of substitution of the conjugate and the quantum yield of the bound fluorophore, and is compared to a common standard (in this case, 7-amino-4-methylcoumarin). The degree of substitution is determined as described earlier (Example 22). The resulting dependence of fluorescence on degree of substitution is shown for streptavidin and goat anti-mouse conjugates in FIGS. 2 and 3 respectively. As shown, as the degree of substitution increases, the total fluorescence increases. The dye-conjugates of Compound 2 exhibit a higher fluorescence output than do the dye-conjugates of AMCA.
Wheat germ agglutinin (WGA) is dissolved at 10 mg/mL in 0.1M sodium bicarbonate pH 8.3, containing N-acetylglucosamine at a reagent-to-protein ratio of 15. The addition of N-acetylglucosamine is necessary to protect the active site of the lectin from reacting with the dye during the conjugation reaction. Compound 2 and AMCA, SE are dissolved at 10 mg/mL in DMF and added to the WGA solutions at a dye-to-protein molar ratio of 5, 10 and 15 and the solutions are stirred for 1 hour at room temperature. Both series of reactions are terminated by the addition of an amount of hydroxylamine to obtain a final concentration of 0.1M, and the resulting conjugates are purified using size exclusion chromatography, as described in Example 22. Both dyes produce conjugates having the degrees of substitution presented in Example 22, and all the conjugates exhibit a similar activity for binding to Gram-positive bacteria, such as Bacillus and Staphylococcus (see Example 32).
Freshly cultured bacteria are washed with water, then boiled in water for 45 minutes. The heat-killed bacteria (5×108 /mL) are labeled with Compound 2 (30 μg/mL) in 0.15M bicarbonate buffer, pH 8.6 at room temperature for 60 minutes with constant stirring. The remaining free dye is removed by washing three times with phosphate buffered saline (PBS), pH 7.4. The resulting labeled bacteria exhibit blue fluorescence.
The efficacy of a goat anti-mouse (GAM) antibody conjugate of Compound 2 is tested in parallel to that of a GAM antibody conjugate of AMCA (both prepared as described in Example 22). The comparison is performed using a test to detect anti-nuclear antibodies commercially available from INOVA Diagnostics Inc. (San Diego, Calif.). The commercial assay consists of a series of fixed cells on slides, and an autoimmune serum against cell nuclei. The GAM conjugate of Compound 2 has a degree of substitution of 4.5 moles of dye per mole of protein, while the GAM conjugate of AMCA, SE has a degree of substitution of 4.4 dyes per mole. The cell nuclei are treated with either positive serum or negative serum (as a control), and are then developed using solutions of either GAM-AMCA or GAM-Compound 2 at a concentration of 1-5 mg/mL. The conjugates of Compound 2 yield brighter nuclear staining and lower fluorescence background than the conjugate prepared using AMCA (approximately 50% more fluorescent, as measured using a fluorescent microscope coupled to a Photometrics Star-1 cooled CCD camera for quantitative digital imaging).
A suspension of GEPA cells (a B-cell lymphoma) is treated with a monoclonal antibody directed against the ICAM adhesion molecule that is expressed on the surface of this cell line. The cells are stained in parallel with GAM-Compound 2 (having a degree of substitution of 4.5) or GAM-AMCA (having a degree of substitution of 4.4). The cells are stained using 5 μg of the desired GAM conjugate per 500,000 GEPA cells in a volume of 200 μL of PBS-BSA. All incubations are performed on ice for 30 minutes, and the cells are washed twice with cold phosphate buffered saline (PBS), 1% BSA, between steps. The washed cells are then analyzed on a FACS Vantage flow cytometer. Typically GEPA cells stained with GAM-Compound 2 exhibit a higher fluorescence than the cells stained with GAM-AMCA. A GAM conjugate fluorescein was utilized as a control for the system. The ratio of fluorescence of stained cells to unstained cells for fluorescein is 15.3, for AMCA is 6.6 and for Compound 2 is 12.4, thus showing the greater brightness of the GAM-Compound 2 conjugate.
A sample of aminodextran (50 mg) having an average molecular weight of 10,000 and derivatized with an average of 3.6 amino groups, is dissolved in 0.1M sodium bicarbonate to give a concentration of 10 mg/mL. A solution of Compound 2 in DMF having a concentration of 10 mg/mL is added to the dextran solution in an amount to give a dye/dextran ratio of 4. After stirring at room temperature, the conjugated dextran is purified by gel filtration using SEPHADEX G-15 resin in water. The dextran solution is lyophilized, and the degree of substitution of the dextran is determined as described in Example 22 for protein conjugates.
Mammalian cells are grown on coverslips according to standard tissue culture procedures. After two days in culture, the growth medium is removed and the cells are rinsed twice with warm Hanks Balanced Salt Solution (HBSS; 0.14 g/L CaCl2, 0.40 g/L KCl, 0.06 g/L KH2 PO4, 0.10 g/L MgCl2.6H2 O, 0.10 g/L MgSO4.7H2 O, 8.0 g/L NaCl, 0.35 g/L NaHCO3, 0.48 g/L Na2 HPO4, 1 g/L D-glucose). Cells are then fixed in 3.7% formaldehyde diluted into HBSS for 10 minutes at room temperature. Cells are rinsed in phosphate buffered saline (PBS; 0.20 g/L KCl, 0.20 g/L KH2 PO4, 8 g/L NaCl, 1.15 g/L Na2 HPO4), and permeabilized in ice cold acetone for 10 minutes. The cells are then rehydrated in PBS for 10 minutes, and stained with a 165 nM solution of a labeled phalloidin (as described in Example 22) in PBS. The stained cells are then rinsed twice with PBS, mounted in the mounting medium of choice, and viewed using a standard filter set used for AMCA conjugates (see next example) on a fluorescence microscope. The staining of F-actin filaments using the phalloidin conjugate is consistent with that of obtained using a longer wavelength dye-conjugate, such as a tetramethylrhodamine phalloidin conjugate, only exhibiting blue fluorescence.
Cells are grown, fixed and permeabilized as described in Example 29. After a 10 minutes rehydration in PBS, cells are blocked in a solution of 1% bovine serum albumin/1% normal goat serum/0.1% TWEEN-20 in PBS for 30 minutes. The nuclei are stained for contrast with SYTOX Green nucleic acid stain (Molecular Probes, Inc., Eugene Oreg.), which only stains cells with compromised cellular membranes. After rinsing in PBS, cells are then incubated with a 165 nm solution of a labeled phalloidin (as described in Example 20) diluted in PBS for 30 minutes. Cells are rinsed a final time in PBS, mounted in the mounting medium of choice, and viewed through either a multi-band filter, or DAPI (ex. 330±30 nm, em.>400 nm) and a fluorescein filter with a standard fluorescence microscope. Simultaneous staining of both F-actin and nuclei is consistent with staining by the individual probes.
For each labeling reaction, a microfuge tube containing about 1 μg of a ˜700 bp Hind III-Bgl II fragment of the E. coli lacZ structural gene is heated for about 10 minutes at 95° C. to fully separate the strands. The DNA is immediately cooled on ice, to prevent the strands from reannealing. To the DNA mixture on ice is added 2 μL of a 2 mg/mL mixture of random sequence hexanucleotides, in 0.5M Tris-HCl, pH 7.2, 0.1M MgCl2, 1 mm dithiothreitol; 2 μL of a dNTP labeling mixture (1 mM dATP, 1 mM dGTP, 1 mM dCTP, 0.65 mM dTTP and 0.35 mM of a dUTP conjugate of Compound 2 (Example 18). Sterile distilled and deionized water is added to the samples to bring the total volume of each to 19 μL. A 1 μL volume of Klenow DNA polymerase (2 units/μL) is added carefully to the samples and they are mixed by pipetting up and down repeatedly. The samples are incubated for one hour at 37° C. The reaction is stopped by adding 2 μL of 0.2M EDTA, pH 8.0. The labeled DNA is precipitated by addition of 2.5 μL of 4M LiCl and 75 μL prechilled (-20° C.) 100% ethanol and mixing well. Precipitation is allowed to continue for 2 hours at -20° C. and the nucleic acid is then recovered by centrifugation at 5000 rpm in a microfuge. The pellet is washed briefly with cold 70% ethanol, then with cold 100% ethanol. The pellet is dried briefly and dissolved in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA. A portion consisting of 1/10 to 1/2 of the sample is analyzed by gel electrophoresis on a 1% agarose minigel under standard conditions. The Compound 2-labeled dUTP (Compound 17) gives rise to clearly visible labeled DNA products that exhibit bright blue fluorescence when visualized using ultraviolet trans- or epi-illumination. The labeled DNA products are suitable for in situ hybridization experiments for the detection of RNA or DNA associated with the E. coli lacZ gene in cells or tissues.
A 2 mg/mL stock solution of a wheat germ agglutinin conjugate of AMCA (as prepared in Example 24) is prepared using 0.1M sodium bicarbonate at pH 8.3. A 100 μL aliquot of a bacterial suspension of either Bacillus subtilis or Staphylococcus aureus (approximately 5×107 cells) is centrifuged in a 0.2 μm-pore size spin filter at 2000 rpm for 1-2 minutes. The cells are then washed by pipetting up and down several times in 100 μL of a solution containing 0.25% bovine serum albumin and 0.15M NaCl. The cells are then recentrifuged as above, and resuspended in 100 μL of the BSA-saline solution. A 5.0 μL aliquot of the dye-WGA conjugate stock solution is added, and mixed well. The sample is then incubated for 5-15 minutes at room temperature. The stained sample is centrifuged at 2000 rpm for 1-2 minutes to remove the staining solution, and the bacteria are resuspended in 100 μL of the BSA-saline solution. Approximately 10 μL of the suspension is transferred to a slide, a coverslip is applied and sealed, and the sample is observed immediately using a fluorescence microscope. The Gram-positive bacteria exhibit blue fluorescence.
Heat-killed bacteria are prepared and labeled with Compound 2 as described in Example 25. The labeled bacteria are then opsonized either with a 1:50 dilution of rabbit polyclonal anti-bacteria IgG, or with a 1:50 dilution of fresh human serum in PBS, (pH 7.4) at 4° C. for 30 minutes, then washed with PBS. The opsonized bacteria are incubated with human neutrophils at a ratio of 100:1 in PBS at 4° C. for 30 minutes, then at 37° C. for 30 minutes. Following washing with PBS, neutrophils are examined under a microscope to identify the phagocytosis of the labeled bacteria. Phagocytosis is quantitated as a phagocytic index (PI), the number of phagocytosed bacteria in 100 neutrophils. Alternatively, phagocytosis is assessed by flow cytometry using the fluorescence intensity of individual Compound 2 labeled bacteria as the reference to calculate the phagocytosis index.
A solution of Compound 5 dissolved at 10 mg/mL in DMF is added to a solution of β-galactosidase 10 mg/mL in 0.1M phosphate, 0.1M NaCl pH 7.5 at a molar dye-to-protein ratio of 20. The reaction mixture is allowed to stir for 2 hours at room temperature under an argon atmosphere. The availability of ten or more free thiol moieties on the protein results in a degree of substitution of 6.3 dyes per protein for Compound 5. The analogous labeling experiment performed with AMCA maleimide results in a DOS of 4.3 dyes per protein.
It is to be understood that, while the foregoing invention has been described in detail by way of illustration and example, numerous modifications, substitutions, and alterations are possible without departing from the spirit and scope of the invention as described in the following claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4279992 *||Oct 23, 1979||Jul 21, 1981||Miles Laboratories, Inc.||Specific binding assay employing an enzyme-cleavable substrate as label|
|US4473693 *||Aug 4, 1978||Sep 25, 1984||Stewart Walter W||Aminonaphthalimide dyes for intracellular labelling|
|US4711955 *||May 23, 1983||Dec 8, 1987||Yale University||Modified nucleotides and methods of preparing and using same|
|US4956480 *||Dec 2, 1986||Sep 11, 1990||Biocarb Ab||7-amino-4-methyl-coumarin-3-carboxyalkyl derivates and fluorescent conjugates thereof|
|US4997928 *||Sep 15, 1988||Mar 5, 1991||E. I. Du Pont De Nemours And Company||Fluorescent reagents for the preparation of 5'-tagged oligonucleotides|
|US5047519 *||Jun 12, 1987||Sep 10, 1991||E. I. Du Pont De Nemours And Company||Alkynylamino-nucleotides|
|US5049673 *||Oct 30, 1987||Sep 17, 1991||The Regents Of The University Of California||Fluorescent indicator dyes for calcium working at long wavelengths|
|US5171534 *||Oct 15, 1990||Dec 15, 1992||California Institute Of Technology||Automated DNA sequencing technique|
|US5196306 *||Sep 28, 1990||Mar 23, 1993||E. I. Du Pont De Nemours And Company||Method for the detection or quantitation of an analyte using an analyte dependent enzyme activation system|
|US5332666 *||Oct 22, 1991||Jul 26, 1994||E. I. Du Pont De Nemours And Company||Method, system and reagents for DNA sequencing|
|US5405975 *||Mar 29, 1993||Apr 11, 1995||Molecular Probes, Inc.||Fluorescent ion-selective diaryldiaza crown ether conjugates|
|US5453517 *||Feb 25, 1992||Sep 26, 1995||Molecular Probes, Inc.||Reactive derivatives of bapta used to make ion-selective chelators|
|US5514710 *||Jan 11, 1994||May 7, 1996||Molecular Probes, Inc.||Photocleavable derivatives of hydroxyprenesulfonic acids|
|US5516911 *||Dec 30, 1993||May 14, 1996||The United States Of America As Represented By The Department Of Health And Human Services||Fluorescent intracellular calcium indicators|
|DE3044128A1 *||Nov 24, 1980||Jul 15, 1982||Bayer Ag||Sulphonated hydroxy coumarin cpds. - for dyeing cellulosic and amide material, esp. paper to prevent fraud|
|EP0608737A1 *||Jan 17, 1994||Aug 3, 1994||Bayer Ag||Sulpho-cumarin containing nucleotiden and their use in detection methods for nucleic acids|
|WO1994005688A1 *||Sep 1, 1993||Mar 17, 1994||Applied Biosystems, Inc.||4,7-dichlorofluorescein dyes as molecular probes|
|1||*||Abd El Hafez, et al., Egypt. J. Pharm. Sci., 35, 113 (1994).|
|2||Abd-El-Hafez, et al., Egypt. J. Pharm. Sci., 35, 113 (1994).|
|3||*||Angelides, et al., J. Biol. Chem., 258, pp. 11948 11957, (1983).|
|4||Angelides, et al., J. Biol. Chem., 258, pp. 11948-11957, (1983).|
|5||*||Besson, Hetrocycles, 34, No. 2. 273 (1992).|
|6||*||Brinkley, et al., Bioconjugate Chem., 3, 2 13 (1992).|
|7||Brinkley, et al., Bioconjugate Chem., 3, 2-13 (1992).|
|8||*||Haugland, et al., Meth. Mol. Biol. 45, 205 (1995).|
|9||*||Haugland, Molecular Probes Handbook of Fluorescent Probes and Research Chemicals, Sets 1 7 (1992).|
|10||Haugland, Molecular Probes Handbook of Fluorescent Probes and Research Chemicals, Sets 1-7 (1992).|
|11||*||Hermanson, Bioconjugate Techniques, Academic Press (1996).|
|12||*||Jackson, Meth. Enzymol., 230, 250 (1994).|
|13||*||Mandour, et al., Egypt. J. Pharm. Sci., 36, 71 (1995).|
|14||*||Merchant, et al., J. Indian Chem. Soc., 34, 35 (1957).|
|15||*||O Shea, et al., Electrophoresis, 17, 681 (1996).|
|16||O'Shea, et al., Electrophoresis, 17, 681 (1996).|
|17||*||Raju, et al. Am. J. Physiol., 256, C540 C548, (1989).|
|18||Raju, et al. Am. J. Physiol., 256, C540-C548, (1989).|
|19||*||Wittung, et al., Nature, 368, 561 (1994).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5994067 *||Nov 12, 1996||Nov 30, 1999||The United States Of America As Represented By The Secretary Of The Army||Method and kit for rapid detection of toxins and bacteria|
|US6130101 *||Sep 23, 1997||Oct 10, 2000||Molecular Probes, Inc.||Sulfonated xanthene derivatives|
|US6169185||Feb 25, 1999||Jan 2, 2001||Day-Glo Color Corp.||Ink jet printing inks|
|US6323337||May 12, 2000||Nov 27, 2001||Molecular Probes, Inc.||Quenching oligonucleotides|
|US6372512||Sep 16, 1998||Apr 16, 2002||Resolution Sciences Corporation||Combined en bloc staining and embedding process|
|US6399392||Apr 21, 2000||Jun 4, 2002||Molecular Probes, Inc.||Xanthene dyes and their application as luminescence quenching compounds|
|US6555332 *||May 4, 2001||Apr 29, 2003||Biomerieux S.A.||Fluorescent detection method for microorganisms based on nitrocoumarins|
|US6716979||Aug 4, 2001||Apr 6, 2004||Molecular Probes, Inc.||Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings|
|US6953694 *||Dec 6, 2000||Oct 11, 2005||The Trustees Of Columbia University In The City Of New York||Attachment of second harmonic-active moiety to molecules for detection of molecules at interfaces|
|US6962992||Dec 19, 2001||Nov 8, 2005||Molecullar Probes, Inc.||Crown ether derivatives|
|US7102005||May 2, 2003||Sep 5, 2006||Molecular Probes, Inc.||Compositions and methods for detection and isolation of phosphorylated molecules|
|US7105310 *||Jul 19, 2000||Sep 12, 2006||California Institute Of Technology||Detection of biomolecules by sensitizer-linked substrates|
|US7150967||Apr 4, 2003||Dec 19, 2006||University Of Medicine & Dentistry Of New Jersey||Fluorescent tags for amino acid and nucleic acid analysis|
|US7271265||Aug 11, 2004||Sep 18, 2007||Invitrogen Corporation||Cyanine compounds and their application as quenching compounds|
|US7282339||Sep 17, 2004||Oct 16, 2007||Invitrogen Corporation||Competitive immunoassay|
|US7351829||Jul 3, 2002||Apr 1, 2008||Dyomics Gmbh||Compounds on the basis of 2- and 4-chromenylidene-merocyanines respectively, and their use|
|US7445894||Apr 9, 2004||Nov 4, 2008||Molecular Probes, Inc.||Compositions and methods for detection and isolation of phosphorylated molecules|
|US7446202||Dec 6, 2004||Nov 4, 2008||Molecular Probes, Inc.||Cyanine dye compounds|
|US7521577||Jan 12, 2007||Apr 21, 2009||Molecular Probes, Inc.||Heavy metal binding compounds and their method of use|
|US7569695||May 24, 2005||Aug 4, 2009||Enzo Life Sciences, Inc.||Dyes for the detection or quantification of desirable target molecules|
|US7579463||Oct 2, 2006||Aug 25, 2009||Life Technologies Corporation||Crown ether derivatives|
|US7655409||Sep 29, 2008||Feb 2, 2010||Life Technologies Corporation||Cyanine dye compounds|
|US7667024||Nov 19, 2004||Feb 23, 2010||Allelogic Biosciences Corp.||Oligonucleotides labeled with a plurality of fluorophores|
|US7713687||Nov 29, 2001||May 11, 2010||Xy, Inc.||System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations|
|US7723116||May 25, 2006||May 25, 2010||Xy, Inc.||Apparatus, methods and processes for sorting particles and for providing sex-sorted animal sperm|
|US7727752||Jul 14, 2006||Jun 1, 2010||Life Technologies Corporation||Kinase and phosphatase assays|
|US7737281||Jul 7, 2005||Jun 15, 2010||Enzo Life Sciences, Inc. C/O Enzo Biochem, Inc.||Purine based fluorescent dyes|
|US7758811||Mar 29, 2004||Jul 20, 2010||Inguran, Llc||System for analyzing particles using multiple flow cytometry units|
|US7767821||Jun 22, 2009||Aug 3, 2010||Becton, Dickinson & Company||Long wavelength thiol-reactive fluorophores|
|US7771921||Sep 28, 2006||Aug 10, 2010||Xy, Llc||Separation systems of frozen-thawed spermatozoa into X-chromosome bearing and Y-chromosome bearing populations|
|US7776529||Dec 6, 2004||Aug 17, 2010||Life Technologies Corporation||Methine-substituted cyanine dye compounds|
|US7776533||Oct 24, 2006||Aug 17, 2010||Life Technologies Corporation||Compositions and methods for detection and isolation of phosphorylated molecules|
|US7799569||Mar 16, 2009||Sep 21, 2010||Inguran, Llc||Process for evaluating staining conditions of cells for sorting|
|US7816519||Nov 16, 2006||Oct 19, 2010||Life Technologies Corporation||Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings|
|US7820425||Dec 7, 2006||Oct 26, 2010||Xy, Llc||Method of cryopreserving selected sperm cells|
|US7833147||Jul 22, 2005||Nov 16, 2010||Inguran, LLC.||Process for enriching a population of sperm cells|
|US7838210||Mar 29, 2005||Nov 23, 2010||Inguran, LLC.||Sperm suspensions for sorting into X or Y chromosome-bearing enriched populations|
|US7842811||Jan 12, 2010||Nov 30, 2010||Life Technologies Corporation||Cyanine dye compounds|
|US7855078||Aug 15, 2003||Dec 21, 2010||Xy, Llc||High resolution flow cytometer|
|US7892725||Mar 29, 2005||Feb 22, 2011||Inguran, Llc||Process for storing a sperm dispersion|
|US7897328||Mar 23, 2007||Mar 1, 2011||Absorber Ab||Blood group antigens of different types for diagnostic and therapeutic applications|
|US7929137||Sep 8, 2009||Apr 19, 2011||Xy, Llc||Optical apparatus|
|US7943384||Jun 7, 2010||May 17, 2011||Inguran Llc||Apparatus and methods for sorting particles|
|US7943777||Oct 5, 2009||May 17, 2011||Life Technologies Corporation||Fluorescent chemical compounds having high selectivity for double stranded DNA, and methods for their use|
|US7989617||Aug 24, 2009||Aug 2, 2011||Life Technologies Corporation||Crown ether derivatives|
|US8039648||Jun 16, 2009||Oct 18, 2011||Pierce Biotechnology, Inc.||Compounds used as dyes comperable to Alexa Fluor 350 dyes|
|US8067536||Mar 22, 2010||Nov 29, 2011||Life Technologies Corporation||Kinase and phosphatase assays|
|US8071794||Jun 22, 2009||Dec 6, 2011||Becton, Dickinson And Company||Long wavelength thiol-reactive fluorophores|
|US8093012||Oct 13, 2006||Jan 10, 2012||Aureon Laboratories, Inc.||Multiplex in situ immunohistochemical analysis|
|US8124368||Jul 6, 2007||Feb 28, 2012||Life Technologies Corporation||Fluorogenic protein kinase substrates|
|US8129525||Jun 22, 2009||Mar 6, 2012||Becton Dickinson And Company||Long wavelength thiol-reactive fluorophores|
|US8137967||Aug 21, 2006||Mar 20, 2012||Xy, Llc||In-vitro fertilization systems with spermatozoa separated into X-chromosome and Y-chromosome bearing populations|
|US8140148||Jan 9, 2007||Mar 20, 2012||Boston Scientific Scimed Ltd.||Readable probe array for in vivo use|
|US8173698||Feb 29, 2008||May 8, 2012||Life Technologies Corporation||Environmental sensitive fluorogenic compounds and their application for singlet oxygen and protein detection|
|US8183375||Oct 11, 2010||May 22, 2012||Life Technologies Corporation||Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings|
|US8211629||Aug 1, 2003||Jul 3, 2012||Xy, Llc||Low pressure sperm cell separation system|
|US8304195||Mar 12, 2008||Nov 6, 2012||Life Technologies Corporation||Antibody complexes and methods for immunolabeling|
|US8318450||Jun 22, 2011||Nov 27, 2012||Life Technologies Corporation||Optically-detectable enzyme substrates and their method of use|
|US8404456||Feb 28, 2011||Mar 26, 2013||Absorber Ab||Blood group antigens of different types for diagnostic and therapeutic applications|
|US8431416 *||Mar 17, 2010||Apr 30, 2013||Becton, Dickinson And Company||Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates|
|US8445702||Feb 18, 2011||May 21, 2013||Life Technologies Corporation||Zinc binding compounds and their method of use|
|US8470529||Aug 5, 2010||Jun 25, 2013||Life Technologies Corporation||Methine-substituted cyanine dye compounds|
|US8486618||Jul 18, 2011||Jul 16, 2013||Xy, Llc||Heterogeneous inseminate system|
|US8497063||Aug 24, 2010||Jul 30, 2013||Xy, Llc||Sex selected equine embryo production system|
|US8513451||May 30, 2008||Aug 20, 2013||Hee Chol Kang||Fluorescent phospholipase A2 indicators|
|US8535894||Sep 11, 2012||Sep 17, 2013||Life Technologies Corporation||Antibody complexes and methods for immunolabeling|
|US8551408||Jan 24, 2007||Oct 8, 2013||Life Technologies Corporation||Device and methods for quantifying analytes|
|US8562802||Aug 19, 2011||Oct 22, 2013||Life Technologies Corporation||Transilluminator base and scanner for imaging fluorescent gels, charging devices and portable electrophoresis systems|
|US8586743||Jan 30, 2008||Nov 19, 2013||Life Technologies Corporation||Labeling reagents and methods of their use|
|US8623282||Sep 12, 2012||Jan 7, 2014||Life Technologies Corporation||Device and methods for quantifying analytes|
|US8652769||Aug 9, 2010||Feb 18, 2014||Xy, Llc||Methods for separating frozen-thawed spermatozoa into X-chromosome bearing and Y-chromosome bearing populations|
|US8658434||Oct 28, 2009||Feb 25, 2014||Biotium, Inc.||Fluorescent pyrene compounds|
|US8664006||Mar 1, 2013||Mar 4, 2014||Inguran, Llc||Flow cytometer apparatus and method|
|US8680320||Dec 11, 2009||Mar 25, 2014||Life Technologies Corporation||Heavy metal binding compounds and their method of use|
|US8709817||Feb 7, 2013||Apr 29, 2014||Inguran, Llc||Systems and methods for sorting particles|
|US8709825||Mar 1, 2013||Apr 29, 2014||Inguran, Llc||Flow cytometer method and apparatus|
|US8716033||Feb 12, 2007||May 6, 2014||Life Technologies Corporation||Oligosaccharide modification and labeling of proteins|
|US8748183||Feb 7, 2013||Jun 10, 2014||Inguran, Llc||Method and apparatus for calibrating a flow cytometer|
|US8785208||Jul 29, 2011||Jul 22, 2014||Life Technologies Corporation||Fluorescent metal ion indicators with large stokes shifts|
|US8785212||Jan 14, 2011||Jul 22, 2014||Life Technologies Corporation||Oligosaccharide modification and labeling of proteins|
|US8846925||May 14, 2012||Sep 30, 2014||Life Technologies Corporation||Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings|
|US8865891||Sep 13, 2012||Oct 21, 2014||Life Technologies Corporation||Optically-detectable enzyme substrates and their method of use|
|US8865904||Apr 11, 2013||Oct 21, 2014||Life Technologies Corporation||Fluorescent chemical compounds having high selectivity for double stranded DNA, and methods for their use|
|US8974651||Apr 17, 2011||Mar 10, 2015||C.C. Imex||Illuminator for visualization of fluorophores|
|US9040304||Mar 12, 2014||May 26, 2015||Inguran, Llc||Multi-channel system and methods for sorting particles|
|US9040561||May 24, 2013||May 26, 2015||Life Technologies Corporation||Methine-substituted cyanine dye compounds|
|US9097667||Dec 12, 2008||Aug 4, 2015||Biotium, Inc.||Fluorescent compounds|
|US9115397||Sep 17, 2014||Aug 25, 2015||Life Technologies Corporation||Fluorescent chemical compounds having high selectivity for double stranded DNA, and methods for their use|
|US9140706||Aug 21, 2013||Sep 22, 2015||Life Technologies Corporation||Labeling reagents and methods of their use|
|US9150922||Dec 17, 2013||Oct 6, 2015||Life Technologies Corporation||Cyanine compounds and their application as quenching compounds|
|US9164099||May 8, 2013||Oct 20, 2015||Life Technologies Corporation||Site-specific labeling of affinity tags in fusion proteins|
|US9182406||Aug 4, 2009||Nov 10, 2015||Biodesy, Inc.||Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability|
|US9365822||Feb 11, 2013||Jun 14, 2016||Xy, Llc||System and method for sorting cells|
|US9366676||Jul 13, 2015||Jun 14, 2016||Life Technologies Corporation|
|US9372181||Jun 17, 2014||Jun 21, 2016||Life Technologies Corporation||Fluorescent metal ion indicators with large stokes shifts|
|US9372194||Dec 17, 2014||Jun 21, 2016||Ramdas Pai||Fluorescent dyes, labeled conjugates and analytical methods|
|US9377390||Apr 10, 2015||Jun 28, 2016||Inguran, Llc||Apparatus, methods and processes for sorting particles and for providing sex-sorted animal sperm|
|US9383361||Nov 20, 2014||Jul 5, 2016||Biodesy, Inc.||Methods for detecting allosteric modulators of protein|
|US9395358||Apr 25, 2013||Jul 19, 2016||Biodesy, Inc.||Methods for detecting allosteric modulators of protein|
|US9403985||Mar 19, 2015||Aug 2, 2016||Life Technologies Corporation||Methine-substituted cyanine dye compounds|
|US9422523||Feb 11, 2013||Aug 23, 2016||Xy, Llc||System and method for sorting cells|
|US9428789||Mar 21, 2012||Aug 30, 2016||Biodesy, Inc.||Classification of kinase inhibitors using nonlinear optical techniques|
|US9504405||Oct 23, 2013||Nov 29, 2016||Verily Life Sciences Llc||Spatial modulation of magnetic particles in vasculature by external magnetic field|
|US9562259||Mar 12, 2012||Feb 7, 2017||Ventana Medical Systems, Inc.||Method of analyzing chromosomal inversions|
|US20030045717 *||Jul 3, 2002||Mar 6, 2003||Dyomics Gmbh||Compounds on the basis of 2 and 4-chromeenylidene-merocyaninese respectively, and their use|
|US20040018517 *||Apr 4, 2003||Jan 29, 2004||Laskin Jeffrey D.||Fluorescent tags for amino acid and nucleic acid analysis|
|US20040171034 *||Nov 7, 2003||Sep 2, 2004||Brian Agnew||Compositions and methods for detection and isolation of phosphorylated molecules|
|US20050069962 *||Oct 2, 2002||Mar 31, 2005||Archer Robert M||Antibody complexes and methods for immunolabeling|
|US20050191643 *||Aug 11, 2004||Sep 1, 2005||Rosaria Haugland||Cyanine compounds and their application as quenching compounds|
|US20050233465 *||Apr 14, 2005||Oct 20, 2005||Bioprocessors Corp.||Compositions of matter useful as pH indicators and related methods|
|US20050250214 *||May 5, 2004||Nov 10, 2005||Gee Kyle R||Zinc binding compounds and their method of use|
|US20050272053 *||Nov 19, 2004||Dec 8, 2005||Fei Mao||Oligonucleotides labeled with a plurality of fluorophores|
|US20060160068 *||Sep 17, 2004||Jul 20, 2006||Joseph Beechem||Competitive immunoassay|
|US20060269926 *||May 24, 2005||Nov 30, 2006||Yuejun Xiang||Novel dyes for the detection or quantification of desirable target molecules|
|US20060269931 *||Jul 7, 2005||Nov 30, 2006||Maciej Szczepanik||Purine based fluorescent dyes|
|US20070043212 *||Oct 2, 2006||Feb 22, 2007||Molecular Probes, Inc.||Crown ether derivatives|
|US20070093652 *||Nov 16, 2006||Apr 26, 2007||Invitrogen Corporation||Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings|
|US20070112180 *||Aug 29, 2006||May 17, 2007||California Institute Of Technology||Detection of biomolecules by sensitizer-linked substrates|
|US20070154958 *||Oct 13, 2006||Jul 5, 2007||Aureon Laboratories, Inc.||Multiplex in situ immunohistochemical analysis|
|US20070161112 *||Jan 12, 2007||Jul 12, 2007||Invitrogen Corporation||Heavy metal binding compounds and their method of use|
|US20070190597 *||Feb 12, 2007||Aug 16, 2007||Invitrogen Corporation||Oligosaccharide modification and labeling of proteins|
|US20070224652 *||Mar 23, 2007||Sep 27, 2007||Jan Holgersson||Blood Group Antigens of Different Types for Diagnostic and Therapeutic Applications|
|US20070249014 *||Feb 12, 2007||Oct 25, 2007||Invitrogen Corporation||Labeling and detection of post translationally modified proteins|
|US20080039630 *||Jul 24, 2007||Feb 14, 2008||Invitrogen Corporation||Cyanine compounds and their application as quenching compounds|
|US20080160627 *||Feb 29, 2008||Jul 3, 2008||Invitrogen Corporation||Environmental Sensitive Fluorogenic Compounds and Their Application for Singlet Oxygen and Protein Detection|
|US20090004753 *||Jan 30, 2008||Jan 1, 2009||Invitrogen Corporation||Labeling reagents and methods of their use|
|US20090124511 *||Mar 12, 2008||May 14, 2009||Invitrogen Corporation||Antibody complexes and methods for immunolabeling|
|US20090305410 *||Dec 12, 2008||Dec 10, 2009||Biotium, Inc.||Fluorescent compounds|
|US20100003763 *||Jun 22, 2009||Jan 7, 2010||Becton, Dickinson And Company||Long wavelength thiol-reactive fluorophores|
|US20100009342 *||Jul 10, 2009||Jan 14, 2010||Life Technologies Corporation||Control of chemical modification|
|US20100167320 *||Aug 6, 2009||Jul 1, 2010||Life Technologies Corporation||Compositions and Methods for Detecting and Quantifying Toxic Substances in Disease States|
|US20100203564 *||May 30, 2008||Aug 12, 2010||Life Technologies Corporation||Fluorescent Phospholipase A2 Indicators|
|US20100240103 *||Dec 23, 2009||Sep 23, 2010||Fei Mao||Oligonucleotides labeled with a plurality of fluorophores|
|US20100255504 *||Mar 17, 2010||Oct 7, 2010||Becton, Dickinson And Company||Reactive Heterocycle-Substituted 7-Hydroxycoumarins and Their Conjugates|
|US20100317045 *||Jun 16, 2009||Dec 16, 2010||Pierce Biotechnology, Inc.||Compounds used as dyes comperable to alexa fluor 350 dyes|
|US20110027800 *||Oct 11, 2010||Feb 3, 2011||Life Technologies Corporation||Derivatives of 1,2-dihydro-7-hydroxyquinolines Containing Fused Rings|
|US20110059018 *||Aug 20, 2010||Mar 10, 2011||Sanofi-Aventis||Covalently binding imaging probes|
|US20110097735 *||Oct 28, 2009||Apr 28, 2011||Biotium, Inc.||Fluorescent pyrene compounds|
|US20110105362 *||Jan 12, 2011||May 5, 2011||Life Technologies Corporation||Cyanine compounds and their application as quenching compounds|
|US20110159517 *||Feb 18, 2011||Jun 30, 2011||Life Technologies Corporation||Zinc binding compounds and their method of use|
|US20110184168 *||Jun 22, 2009||Jul 28, 2011||Becton, Dickinson And Company||Long wavelength thiol-reactive fluorophores|
|US20110207171 *||Jan 14, 2011||Aug 25, 2011||Life Technologies Corporation||Oligosaccharide modification and labeling of proteins|
|DE10021256A1 *||Apr 20, 2000||Oct 31, 2001||Forschungsverbund Berlin Ev||Neue, photolabile Cumarinylmethylester von cyclischen Nucleotiden, Verfahren zu deren Herstellung und ihre Verwendung|
|EP1546359A2 *||Sep 12, 2003||Jun 29, 2005||Molecular Probes Inc.||Site-specific labeling of affinity tags in fusion proteins|
|EP1546359A4 *||Sep 12, 2003||May 9, 2007||Molecular Probes Inc||Site-specific labeling of affinity tags in fusion proteins|
|EP2036953A2||May 20, 2005||Mar 18, 2009||Becton, Dickinson & Company||Long wavelength thiol-reactive fluorophores|
|EP2036953A3 *||May 20, 2005||Jul 14, 2010||Becton, Dickinson & Company||Long wavelength thiol-reactive fluorophores|
|EP2045252A2||Aug 4, 2001||Apr 8, 2009||Molecular Probes, Inc.||Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings|
|EP2113773A2||Oct 2, 2002||Nov 4, 2009||Molecular Probes, Inc.||Antibody complexes and methods for immunolabeling|
|EP2224013A1||Feb 13, 2008||Sep 1, 2010||Life Technologies Corporation||Methods for the determination of telomerase activity using click chemistry|
|EP2259067A2||Oct 2, 2002||Dec 8, 2010||Molecular Probes, Inc.||Methods for immunolabeling|
|EP2362223A2||Mar 23, 2007||Aug 31, 2011||Absorber AB||Blood group antigens of different types for diagnostic and therapeutic applications|
|EP2362224A2||Mar 23, 2007||Aug 31, 2011||Absorber AB||Blood group antigens of different types for diagnostic and therapeutic applications|
|EP2535423A2||Feb 13, 2008||Dec 19, 2012||Life Technologies Corporation||Labeling and detection of nucleic acids|
|EP2623609A2||Feb 12, 2007||Aug 7, 2013||Life Technologies Corporation||Labeling and detection of post translationally modified proteins|
|EP2623610A2||Feb 12, 2007||Aug 7, 2013||Life Technologies Corporation||Labeling and detection of post translationally modified proteins|
|EP2623986A2||Feb 12, 2007||Aug 7, 2013||Life Technologies Corporation||Labeling and detection of post translationally modified proteins|
|EP2727965A1||Oct 26, 2007||May 7, 2014||Life Technologies Corporation||Fluorogenic pH sensitive dyes and their method of use|
|EP2848696A1||Sep 13, 2013||Mar 18, 2015||Sanofi-Aventis Deutschland GmbH||Caspase-1 imaging probes|
|EP2982245A1||Dec 4, 2009||Feb 10, 2016||Enzo Life Sciences, Inc.||Labeling of target molecules, identification of organelles and other applications, novel compositions, methods and kits|
|EP3009147A1||Oct 16, 2014||Apr 20, 2016||INSERM (Institut National de la Santé et de la Recherche Medicale)||Method for treating resistant glioblastoma|
|WO2002012195A1||Aug 4, 2001||Feb 14, 2002||Molecular Probes, Inc.||Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings|
|WO2003030817A2||Oct 2, 2002||Apr 17, 2003||Molecular Probes, Inc.||Antibody complexes and methods for immunolabeling|
|WO2007124464A2||Apr 20, 2007||Nov 1, 2007||Becton, Dickinson And Company||Thermostable proteins and methods of making and using thereof|
|WO2007135571A2||Mar 23, 2007||Nov 29, 2007||Absorber Ab||Blood group antigens of different types for diagnostic and therapeutic applications|
|WO2009019115A1||Jul 17, 2008||Feb 12, 2009||Sanofi-Aventis||Caspase imaging probes|
|WO2009078970A1 *||Dec 12, 2008||Jun 25, 2009||Biotium, Inc.||Fluorescent compounds|
|WO2010065918A1||Dec 4, 2009||Jun 10, 2010||Enzo Life Sciences, Inc.||Labeling of target molecules, identification of organelles and other applications, novel compositions, methods and kits|
|WO2010099137A2||Feb 24, 2010||Sep 2, 2010||Osi Pharmaceuticals, Inc.||In situ methods for monitoring the emt status of tumor cells in vivo|
|WO2011030145A1||Sep 8, 2010||Mar 17, 2011||Enigma Diagnostics Limited||Nucleic acid amplification employing temperature oscillation|
|WO2011082293A1||Dec 30, 2010||Jul 7, 2011||Ventana Medical Systems, Inc.||Methods for producing uniquely specific nucleic acid probes|
|WO2011106495A1||Feb 24, 2011||Sep 1, 2011||Ventana Medical Systems, Inc.||Cytogenic analysis of metaphase chromosomes|
|WO2011106583A1||Feb 25, 2011||Sep 1, 2011||Ventana Medical Systems, Inc.||Polytag probes|
|WO2012022734A2||Aug 16, 2011||Feb 23, 2012||Medimmune Limited||Anti-icam-1 antibodies and methods of use|
|WO2012123387A1||Mar 12, 2012||Sep 20, 2012||F. Hoffmann-La Roche Ag||A method of analyzing chromosomal translocations and a system therefore|
|WO2012151111A1||Apr 26, 2012||Nov 8, 2012||Htg Molecular Diagnostics, Inc.||Quantitative nuclease protection assay (qnpa) and sequencing (qnps) improvements|
|WO2013006195A1||Dec 7, 2011||Jan 10, 2013||Htg Molecular Diagnostics, Inc.||Methods of detecting gene fusions|
|WO2013057586A1||Oct 19, 2012||Apr 25, 2013||Oslo Universitetssykehus Hf||Compositions and methods for producing soluble t - cell receptors|
|WO2013108126A2||Jan 14, 2013||Jul 25, 2013||University Of Oslo||Methyltransferases and uses thereof|
|WO2013167387A1||Apr 25, 2013||Nov 14, 2013||Ventana Medical Systems, Inc.||Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2|
|WO2014009535A2||Jul 12, 2013||Jan 16, 2014||INSERM (Institut National de la Santé et de la Recherche Médicale)||Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes|
|WO2014048942A1||Sep 25, 2013||Apr 3, 2014||Ventana Medical Systems, Inc.||Probes for pten, pik3ca, met, and top2a, and method for using the probes|
|WO2014066733A2||Oct 25, 2013||May 1, 2014||Life Technologies Corporation||Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins|
|WO2015036405A1||Sep 9, 2014||Mar 19, 2015||INSERM (Institut National de la Santé et de la Recherche Médicale)||Methods for diagnosing and treating basal cell carcinoma|
|WO2015050959A1||Oct 1, 2014||Apr 9, 2015||Yale University||Anti-kit antibodies and methods of use thereof|
|WO2016113233A1||Jan 12, 2016||Jul 21, 2016||INSERM (Institut National de la Santé et de la Recherche Médicale)||Methods for the diagnosis of pancreatic cancer|
|WO2017029391A1||Aug 19, 2016||Feb 23, 2017||INSERM (Institut National de la Santé et de la Recherche Médicale)||New method for treating cancer|
|U.S. Classification||514/457, 549/285, 549/289, 549/288|
|International Classification||C07D311/16, C07D405/12|
|Cooperative Classification||C07D405/12, C07D311/16|
|European Classification||C07D311/16, C07D405/12|
|Nov 15, 1996||AS||Assignment|
Owner name: MOLECULAR PROBES, INC., OREGON
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, HUI-YING;LEUNG, WAI-YEE;MAO, FEI;REEL/FRAME:008316/0115
Effective date: 19961115
|Oct 31, 2000||CC||Certificate of correction|
|Apr 26, 2001||FPAY||Fee payment|
Year of fee payment: 4
|Jun 3, 2005||FPAY||Fee payment|
Year of fee payment: 8
|Dec 5, 2008||AS||Assignment|
Owner name: BANK OF AMERICA, N.A., WASHINGTON
Free format text: SECURITY AGREEMENT;ASSIGNOR:MOLECULAR PROBES, INC.;REEL/FRAME:021930/0243
Effective date: 20081121
Owner name: BANK OF AMERICA, N.A.,WASHINGTON
Free format text: SECURITY AGREEMENT;ASSIGNOR:MOLECULAR PROBES, INC.;REEL/FRAME:021930/0243
Effective date: 20081121
|Jun 9, 2009||FPAY||Fee payment|
Year of fee payment: 12
|Apr 8, 2013||AS||Assignment|
Owner name: MOLECULAR PROBES, INC., OREGON
Free format text: LIEN RELEASE;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:030173/0561
Effective date: 20100528